Activation-dependent	O
transcriptional	O
regulation	O
of	O
the	O
human	B-DNA
Fas	I-DNA
promoter	I-DNA
requires	O
NF-kappaB	B-protein
p50-p65	I-protein
recruitment	O
.	O

Fas	B-protein
(	O
CD95	B-protein
)	O
and	O
Fas	B-protein
ligand	I-protein
(	O
CD95L	B-protein
)	O
are	O
an	O
interacting	O
receptor-ligand	O
pair	O
required	O
for	O
immune	O
homeostasis	O
.	O

Lymphocyte	O
activation	O
results	O
in	O
the	O
upregulation	O
of	O
Fas	B-protein
expression	O
and	O
the	O
acquisition	O
of	O
sensitivity	O
to	O
FasL	B-protein
-mediated	O
apoptosis	O
.	O

Although	O
Fas	O
upregulation	O
is	O
central	O
to	O
the	O
preservation	O
of	O
immunologic	O
tolerance	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
machinery	O
underlying	O
this	O
process	O
.	O

To	O
investigate	O
the	O
events	O
involved	O
in	O
activation-induced	O
Fas	B-protein
upregulation	O
,	O
we	O
have	O
examined	O
mRNA	O
accumulation	O
,	O
fas	O
promoter	O
activity	O
,	O
and	O
protein	O
expression	O
in	O
the	O
Jurkat	B-cell_line
T-cell	I-cell_line
line	I-cell_line
treated	O
with	O
phorbol	O
myristate	O
acetate	O
and	O
ionomycin	O
(	O
P/I	O
)	O
,	O
pharmacological	O
mimics	O
of	O
T-cell	B-protein
receptor	I-protein
activation	O
.	O

Although	O
resting	B-cell_line
Jurkat	I-cell_line
cells	I-cell_line
express	O
Fas	B-protein
,	O
Fas	B-RNA
mRNA	I-RNA
was	O
induced	O
approximately	O
10-fold	O
in	O
2	O
h	O
upon	O
P/I	O
stimulation	O
.	O

Using	O
sequential	B-DNA
deletion	I-DNA
mutants	I-DNA
of	O
the	O
human	B-DNA
fas	I-DNA
promoter	I-DNA
in	O
transient	O
transfection	O
assays	O
,	O
we	O
identified	O
a	O
47-bp	B-DNA
sequence	I-DNA
(	O
positions	B-DNA
-306	I-DNA
to	I-DNA
-260	I-DNA
relative	O
to	O
the	O
ATG	O
)	O
required	O
for	O
activation-driven	O
fas	O
upregulation	O
.	O

Sequence	O
analysis	O
revealed	O
the	O
presence	O
of	O
a	O
previously	O
unrecognized	B-DNA
composite	I-DNA
binding	I-DNA
site	I-DNA
for	O
both	O
the	O
Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	B-protein
factors	I-protein
at	O
positions	B-DNA
-295	I-DNA
to	I-DNA
-286	I-DNA
.	O

Electrophoretic	O
mobility	O
shift	O
assay	O
(	O
EMSA	O
)	O
and	O
supershift	O
analyses	O
of	O
this	O
region	O
documented	O
constitutive	O
binding	O
of	O
Sp1	B-protein
in	O
unactivated	O
nuclear	O
extracts	O
and	O
inducible	O
binding	O
of	O
p50-p65	B-protein
NF-kappaB	I-protein
heterodimers	I-protein
after	O
P/I	O
activation	O
.	O

Sp1	B-protein
and	O
NF-kappaB	B-protein
transcription	O
factor	O
binding	O
was	O
shown	O
to	O
be	O
mutually	O
exclusive	O
by	O
EMSA	O
displacement	O
studies	O
with	O
purified	O
recombinant	O
Sp1	B-protein
and	O
recombinant	O
p50	B-protein
.	O

The	O
functional	O
contribution	O
of	O
the	O
kappaB-Sp1	B-DNA
composite	I-DNA
site	I-DNA
in	O
P/I-inducible	B-DNA
fas	I-DNA
promoter	I-DNA
activation	O
was	O
verified	O
by	O
using	O
kappaB-	O
Sp1	B-protein
concatamers	O
(	O
-295	B-DNA
to	I-DNA
-286	I-DNA
)	O
in	O
a	O
thymidine	B-DNA
kinase	I-DNA
promoter-driven	I-DNA
reporter	I-DNA
construct	I-DNA
and	O
native	B-DNA
promoter	I-DNA
constructs	I-DNA
in	O
Jurkat	B-cell_line
cells	I-cell_line
overexpressing	O
IkappaB-alpha	B-protein
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
critical	O
guanine	O
nucleotides	O
in	O
the	O
kappaB-Sp1	B-DNA
element	I-DNA
documented	O
the	O
essential	O
role	O
of	O
this	O
site	O
in	O
activation-dependent	O
fas	O
promoter	O
induction	O
.	O

MoLECcULAR	NULL
AND	NULL
CELLULAR	NULL
BroLOoGY	NULL
,	NULL
Mar	NULL
.	NULL

1999	NULL
,	NULL
p.	NULL
2098-2108	NULL
0270-7306/99/	NULL
$	NULL
04.00+0	NULL
Vol	NULL
.	NULL

19	NULL
,	NULL
No	NULL
.	NULL

3	NULL
Copyright	NULL
©	NULL
1999	NULL
,	NULL
American	NULL
Society	NULL
for	NULL
Microbiology	NULL
.	NULL

All	NULL
Rights	NULL
Reserved	NULL
.	NULL

Activation-Dependent	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
the	NULL
Human	NULL
Jas	NULL
Promoter	NULL
Requires	NULL
NF-	NULL
«	NULL
B	NULL
p50-p65	NULL
Recruitment	NULL
HENRY	NULL
CHAN	NULL
,	NULL
DAVID	NULL
P.	NULL
BARTOS	NULL
,	NULL
anp	NULL
LAURIE	NULL
B.	NULL
OWEN-SCHAUB*	NULL
Department	NULL
of	NULL
Immunology	NULL
,	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
Houston	NULL
,	NULL
Texas	NULL
77030	NULL
Received	NULL
19	NULL
June	NULL
1998/Returned	NULL
for	NULL
modification	NULL
14	NULL
August	NULL
1998/Accepted	NULL
10	NULL
December	NULL
1998	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
and	NULL
Fas	NULL
ligand	NULL
(	NULL
CD95L	NULL
)	NULL
are	NULL
an	NULL
interacting	NULL
receptor-ligand	NULL
pair	NULL
required	NULL
for	NULL
immune	NULL
homeosta-sis	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
results	NULL
in	NULL
the	NULL
upregulation	NULL
of	NULL
Fas	NULL
expression	NULL
and	NULL
the	NULL
acquisition	NULL
of	NULL
sensitivity	NULL
to	NULL
FasL-mediated	NULL
apoptosis	NULL
.	NULL

Although	NULL
Fas	NULL
upregulation	NULL
is	NULL
central	NULL
to	NULL
the	NULL
preservation	NULL
of	NULL
immunologic	NULL
tolerance	NULL
,	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
molecular	NULL
machinery	NULL
underlying	NULL
this	NULL
process	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
events	NULL
involved	NULL
in	NULL
activation-induced	NULL
Fas	NULL
upregulation	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
mRNA	NULL
accumulation	NULL
,	NULL
fas	NULL
promoter	NULL
activity	NULL
,	NULL
and	NULL
protein	NULL
expression	NULL
in	NULL
the	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
treated	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
and	NULL
ionomycin	NULL
(	NULL
P/D	NULL
)	NULL
,	NULL
pharmacological	NULL
mimics	NULL
of	NULL
T-cell	NULL
receptor	NULL
activation	NULL
.	NULL

Although	NULL
resting	NULL
Jurkat	NULL
cells	NULL
express	NULL
Fas	NULL
,	NULL
Fas	NULL
mRNA	NULL
was	NULL
induced	NULL
approximately	NULL
10-fold	NULL
in	NULL
2	NULL
h	NULL
upon	NULL
P/I	NULL
stimulation	NULL
.	NULL

Using	NULL
sequential	NULL
deletion	NULL
mutants	NULL
of	NULL
the	NULL
human	NULL
fas	NULL
promoter	NULL
in	NULL
transient	NULL
transfection	NULL
assays	NULL
,	NULL
we	NULL
identified	NULL
a	NULL
47-bp	NULL
sequence	NULL
(	NULL
positions	NULL
-306	NULL
to	NULL
-260	NULL
relative	NULL
to	NULL
the	NULL
ATG	NULL
)	NULL
required	NULL
for	NULL
activation-driven	NULL
fas	NULL
upregulation	NULL
.	NULL

Sequence	NULL
analysis	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
previously	NULL
unrecognized	NULL
composite	NULL
binding	NULL
site	NULL
for	NULL
both	NULL
the	NULL
Spl	NULL
and	NULL
NF-KB	NULL
transcription	NULL
factors	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
and	NULL
supershift	NULL
analyses	NULL
of	NULL
this	NULL
region	NULL
documented	NULL
constitutive	NULL
binding	NULL
of	NULL
Spl	NULL
in	NULL
unactivated	NULL
nuclear	NULL
extracts	NULL
and	NULL
inducible	NULL
binding	NULL
of	NULL
p50-p65	NULL
NF-KB	NULL
heterodimers	NULL
after	NULL
P/I	NULL
activation	NULL
.	NULL

Spl	NULL
and	NULL
NF-B	NULL
transcription	NULL
factor	NULL
binding	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
mutually	NULL
exclusive	NULL
by	NULL
EMSA	NULL
displacement	NULL
studies	NULL
with	NULL
purified	NULL
recombinant	NULL
Spl	NULL
and	NULL
recombinant	NULL
p50	NULL
.	NULL

The	NULL
functional	NULL
contribution	NULL
of	NULL
the	NULL
«	NULL
B-Spl	NULL
composite	NULL
site	NULL
in	NULL
P/I-inducible	NULL
fas	NULL
promoter	NULL
activation	NULL
was	NULL
verified	NULL
by	NULL
using	NULL
B-Sp1	NULL
concatamers	NULL
(	NULL
-295	NULL
to	NULL
-286	NULL
)	NULL
in	NULL
a	NULL
thymidine	NULL
kinase	NULL
promoter-driven	NULL
reporter	NULL
construct	NULL
and	NULL
native	NULL
promoter	NULL
constructs	NULL
in	NULL
Jurkat	NULL
cells	NULL
overexpressing	NULL
Site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
critical	NULL
guanine	NULL
nucleotides	NULL
in	NULL
the	NULL
xB-Sp1	NULL
element	NULL
documented	NULL
the	NULL
essential	NULL
role	NULL
of	NULL
this	NULL
site	NULL
in	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

Lymphocyte	NULL
activation	NULL
results	NULL
in	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
number	NULL
of	NULL
gene	NULL
products	NULL
that	NULL
mobilize	NULL
and	NULL
maintain	NULL
a	NULL
functional	NULL
immune	NULL
response	NULL
.	NULL

Such	NULL
gene	NULL
products	NULL
regulate	NULL
cellular	NULL
differ-entiation	NULL
,	NULL
effector	NULL
function	NULL
,	NULL
and	NULL
clonal	NULL
expansion	NULL
of	NULL
the	NULL
responding	NULL
lymphocyte	NULL
population	NULL
.	NULL

One	NULL
such	NULL
gene	NULL
product	NULL
is	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
,	NULL
a	NULL
cell	NULL
surface	NULL
protein	NULL
known	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
activated	NULL
lymphocytes	NULL
upon	NULL
binding	NULL
to	NULL
its	NULL
cognate	NULL
ligand	NULL
(	NULL
FasL	NULL
)	NULL
.	NULL

The	NULL
essential	NULL
roles	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
in	NULL
the	NULL
maintenance	NULL
of	NULL
peripheral	NULL
self-tolerance	NULL
underscore	NULL
their	NULL
prominence	NULL
as	NULL
homeostatic	NULL
regulators	NULL
of	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
41	NULL
)	NULL
.	NULL

Within	NULL
the	NULL
T-cell	NULL
compartment	NULL
,	NULL
Fas	NULL
is	NULL
expressed	NULL
on	NULL
immature	NULL
thymocytes	NULL
,	NULL
but	NULL
does	NULL
not	NULL
appear	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
thymic	NULL
deletion	NULL
(	NULL
13	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Fas	NULL
expression	NULL
on	NULL
resting	NULL
peripheral	NULL
blood	NULL
lymphocytes	NULL
is	NULL
low	NULL
to	NULL
absent	NULL
(	NULL
26	NULL
,	NULL
37	NULL
,	NULL
41	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Primary	NULL
T-cell	NULL
activation	NULL
results	NULL
in	NULL
upregulation	NULL
of	NULL
fas	NULL
mRNA	NULL
and	NULL
protein	NULL
followed	NULL
by	NULL
the	NULL
gradual	NULL
acquisition	NULL
of	NULL
sensitivity	NULL
to	NULL
Fas-mediated	NULL
apoptosis	NULL
(	NULL
37	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Although	NULL
the	NULL
regulation	NULL
of	NULL
Fas-mediated	NULL
apoptosis	NULL
is	NULL
complex	NULL
,	NULL
involving	NULL
assembly	NULL
of	NULL
the	NULL
intracellular	NULL
proteins	NULL
necessary	NULL
to	NULL
initiate	NULL
the	NULL
apoptotic	NULL
cascade	NULL
(	NULL
7	NULL
,	NULL
40	NULL
)	NULL
and	NULL
an	NULL
absence	NULL
or	NULL
low	NULL
abundance	NULL
of	NULL
inhibitory	NULL
proteins	NULL
,	NULL
such	NULL
as	NULL
FAP-1	NULL
(	NULL
53	NULL
)	NULL
,	NULL
FLIP	NULL
(	NULL
22	NULL
)	NULL
,	NULL
bel-2	NULL
,	NULL
and	NULL
bel-x	NULL
,	NULL
,	NULL
(	NULL
6	NULL
,	NULL
23	NULL
,	NULL
25	NULL
)	NULL
,	NULL
Fas	NULL
receptor	NULL
cross-linking	NULL
is	NULL
fundamentally	NULL
required	NULL
(	NULL
24	NULL
)	NULL
.	NULL

Fas	NULL
expression	NULL
is	NULL
maintained	NULL
on	NULL
activated	NULL
lymphocytes	NULL
for	NULL
several	NULL
weeks	NULL
(	NULL
44	NULL
)	NULL
,	NULL
and	NULL
upon	NULL
secondary	NULL
exposure	NULL
to	NULL
anti-gen	NULL
,	NULL
FasL	NULL
is	NULL
upregulated	NULL
(	NULL
1	NULL
,	NULL
14	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Autocrine	NULL
or	NULL
paracrine	NULL
interactions	NULL
of	NULL
Fas	NULL
and	NULL
FasL	NULL
result	NULL
in	NULL
the	NULL
apoptotic	NULL
elimination	NULL
of	NULL
responding	NULL
CD4*	NULL
lymphocytes	NULL
,	NULL
a	NULL
process	NULL
termed	NULL
``	NULL
activa-	NULL
*	NULL
Corresponding	NULL
author	NULL
.	NULL

Mailing	NULL
address	NULL
:	NULL
The	NULL
University	NULL
of	NULL
Texas	NULL
M.	NULL
D.	NULL
Anderson	NULL
Cancer	NULL
Center	NULL
,	NULL
1515	NULL
Holcombe	NULL
Blvd	NULL
.	NULL

,	NULL
Box	NULL
178	NULL
,	NULL
Houston	NULL
,	NULL
TX	NULL
77030	NULL
.	NULL

Phone	NULL
:	NULL
(	NULL
713	NULL
)	NULL
792-8735	NULL
.	NULL

Fax	NULL
:	NULL
(	NULL
713	NULL
)	NULL
745-1633	NULL
.	NULL

E-mail	NULL
:	NULL
lowensch	NULL
@	NULL
mdanderson.org	NULL
.	NULL

2098	NULL
tion-induced	NULL
cell	NULL
death	NULL
``	NULL
(	NULL
AICD	NULL
)	NULL
(	NULL
1	NULL
,	NULL
14	NULL
,	NULL
26	NULL
)	NULL
.	NULL

AICD	NULL
can	NULL
also	NULL
be	NULL
induced	NULL
in	NULL
CD4	NULL
*	NULL
T-cell	NULL
lines	NULL
by	NULL
T-cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
engagement	NULL
or	NULL
pharmacological	NULL
mimics	NULL
of	NULL
TCR	NULL
signaling	NULL
,	NULL
such	NULL
as	NULL
anti-CD3	NULL
antibodies	NULL
or	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
)	NULL
plus	NULL
ionomycin	NULL
(	NULL
P/I	NULL
)	NULL
,	NULL
respectively	NULL
.	NULL

In	NULL
direct	NULL
contrast	NULL
,	NULL
activated	NULL
CD8	NULL
*	NULL
T	NULL
cells	NULL
do	NULL
not	NULL
appear	NULL
to	NULL
undergo	NULL
apoptosis	NULL
as	NULL
a	NULL
result	NULL
of	NULL
Fas	NULL
ligation	NULL
,	NULL
but	NULL
rather	NULL
are	NULL
stimulated	NULL
to	NULL
undergo	NULL
clonal	NULL
expansion	NULL
by	NULL
reverse	NULL
signaling	NULL
through	NULL
FasL	NULL
(	NULL
59	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
while	NULL
Fas	NULL
appears	NULL
to	NULL
be	NULL
equivalently	NULL
upregulated	NULL
in	NULL
both	NULL
CD4	NULL
*	NULL
and	NULL
CD8*	NULL
T	NULL
cells	NULL
upon	NULL
activation	NULL
(	NULL
37	NULL
)	NULL
,	NULL
the	NULL
signals	NULL
transduced	NULL
by	NULL
both	NULL
Fas	NULL
and	NULL
FasL	NULL
have	NULL
dissimilar	NULL
biological	NULL
effects	NULL
on	NULL
the	NULL
two	NULL
lymphocyte	NULL
subsets	NULL
.	NULL

The	NULL
transcriptional	NULL
machinery	NULL
controlling	NULL
Fas	NULL
expression	NULL
is	NULL
largely	NULL
unknown	NULL
.	NULL

Genomic	NULL
organization	NULL
studies	NULL
showed	NULL
that	NULL
human	NULL
fas	NULL
is	NULL
a	NULL
single-copy	NULL
gene	NULL
containing	NULL
nine	NULL
exons	NULL
and	NULL
eight	NULL
introns	NULL
,	NULL
spanning	NULL
approximately	NULL
25	NULL
kb	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Sequences	NULL
proximal	NULL
to	NULL
the	NULL
Fas	NULL
translational	NULL
start	NULL
site	NULL
have	NULL
a	NULL
relatively	NULL
high	NULL
GC	NULL
content	NULL
(	NULL
61	NULL
%	NULL
)	NULL
between	NULL
-590	NULL
and	NULL
-1	NULL
,	NULL
a	NULL
number	NULL
of	NULL
CpG	NULL
dinucleotides	NULL
(	NULL
28	NULL
CpGs	NULL
between	NULL
-590	NULL
and	NULL
-1	NULL
)	NULL
,	NULL
and	NULL
an	NULL
absence	NULL
of	NULL
conventional	NULL
TATA	NULL
and	NULL
CAAT	NULL
boxes	NULL
(	NULL
5	NULL
)	NULL
.	NULL

These	NULL
are	NULL
properties	NULL
characteristic	NULL
of	NULL
a	NULL
class	NULL
of	NULL
polymerase	NULL
II-dependent	NULL
promoters	NULL
that	NULL
include	NULL
housekeeping	NULL
genes	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
3	NULL
)	NULL
and	NULL
other	NULL
members	NULL
of	NULL
the	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
TNF	NULL
)	NULL
-nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
superfamily	NULL
(	NULL
28	NULL
,	NULL
51	NULL
,	NULL
52	NULL
,	NULL
54	NULL
)	NULL
.	NULL

Although	NULL
Fas	NULL
is	NULL
constitutively	NULL
expressed	NULL
on	NULL
a	NULL
variety	NULL
of	NULL
nonhematopoietic	NULL
cells	NULL
and	NULL
hematopoietic	NULL
cell	NULL
lines	NULL
(	NULL
33	NULL
,	NULL
43	NULL
)	NULL
,	NULL
multiple	NULL
reports	NULL
have	NULL
documented	NULL
Fas	NULL
inducibility	NULL
in	NULL
response	NULL
to	NULL
such	NULL
stimuli	NULL
as	NULL
UV	NULL
irradiation	NULL
,	NULL
viral	NULL
infection	NULL
,	NULL
wild-type	NULL
p53	NULL
,	NULL
hypoxia	NULL
,	NULL
and	NULL
chemotherapeutic	NULL
agents	NULL
(	NULL
2	NULL
,	NULL
34	NULL
,	NULL
39	NULL
,	NULL
45	NULL
,	NULL
47	NULL
,	NULL
61	NULL
)	NULL
.	NULL

To	NULL
date	NULL
,	NULL
however	NULL
,	NULL
the	NULL
molecular	NULL
events	NULL
regulating	NULL
constitutive	NULL
and	NULL
inducible	NULL
fas	NULL
expression	NULL
have	NULL
not	NULL
been	NULL
elucidated	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
have	NULL
investigated	NULL
the	NULL
transcriptional	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
machinery	NULL
required	NULL
for	NULL
activation-dependent	NULL
induction	NULL
of	NULL
Fas	NULL
expression	NULL
in	NULL
the	NULL
CD4	NULL
*	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
.	NULL

Although	NULL
constitutively	NULL
expressed	NULL
on	NULL
Jurkat	NULL
cells	NULL
,	NULL
Fas	NULL
can	NULL
be	NULL
markedly	NULL
upregulated	NULL
by	NULL
P/I	NULL
activation	NULL
.	NULL

Using	NULL
deletion	NULL
constructs	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
in	NULL
luciferase	NULL
reporter	NULL
assays	NULL
,	NULL
we	NULL
demonstrate	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
previously	NULL
unrecognized	NULL
,	NULL
activation-responsive	NULL
47-bp	NULL
sequence	NULL
containing	NULL
a	NULL
composite	NULL
binding	NULL
site	NULL
for	NULL
both	NULL
Sp1	NULL
and	NULL
NF-xB	NULL
transcription	NULL
factors	NULL
.	NULL

Characterization	NULL
of	NULL
this	NULL
noncanonical	NULL
site	NULL
(	NULL
located	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
)	NULL
by	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
(	NULL
EMSA	NULL
)	NULL
and	NULL
supershift	NULL
analyses	NULL
revealed	NULL
that	NULL
Sp1	NULL
was	NULL
constitutively	NULL
bound	NULL
to	NULL
this	NULL
site	NULL
in	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
,	NULL
while	NULL
p50-p65	NULL
NF-	NULL
«	NULL
B	NULL
heterodimers	NULL
were	NULL
bound	NULL
after	NULL
P/I	NULL
activation	NULL
.	NULL

Site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
critical	NULL
guanine	NULL
nucleotides	NULL
in	NULL
the	NULL
<	NULL
B-Sp1	NULL
site	NULL
,	NULL
as	NULL
well	NULL
as	NULL
inhibition	NULL
of	NULL
IxB	NULL
degradation	NULL
or	NULL
NF-kB	NULL
translocation	NULL
,	NULL
inhibited	NULL
inducible	NULL
Fas	NULL
transcription	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
our	NULL
results	NULL
indicate	NULL
a	NULL
critical	NULL
requirement	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
to	NULL
the	NULL
site	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
in	NULL
activation-driven	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Cell	NULL
culture	NULL
and	NULL
cellular	NULL
activation	NULL
.	NULL

The	NULL
T-lymphoma	NULL
cell	NULL
line	NULL
Jurkat-E6	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Type	NULL
Culture	NULL
Collection	NULL
(	NULL
Rockville	NULL
,	NULL
Md	NULL
.	NULL
)	NULL

and	NULL
cultured	NULL
in	NULL
complete	NULL
medium	NULL
(	NULL
RPMI	NULL
1640	NULL
with	NULL
10	NULL
%	NULL
fetal	NULL
bovine	NULL
serum	NULL
[	NULL
FBS	NULL
]	NULL
and	NULL
2	NULL
mM	NULL
r-glutamine	NULL
)	NULL
at	NULL
0.4	NULL
X	NULL
10°	NULL
to	NULL
0.7	NULL
X	NULL
10°	NULL
cells/ml	NULL
.	NULL

For	NULL
activation	NULL
studies	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
removed	NULL
from	NULL
culture	NULL
and	NULL
washed	NULL
once	NULL
with	NULL
RPMI	NULL
1640	NULL
,	NULL
plated	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
complete	NULL
medium	NULL
,	NULL
and	NULL
rested	NULL
overnight	NULL
.	NULL

The	NULL
following	NULL
day	NULL
,	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
PMA	NULL
(	NULL
50	NULL
ng/m	NULL
!	NULL
)	NULL

and	NULL
ionomycin	NULL
(	NULL
3	NULL
pg/ml	NULL
)	NULL
for	NULL
the	NULL
times	NULL
indicated	NULL
(	NULL
Sigma	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
Mo	NULL
.	NULL
)	NULL

.	NULL

Flow	NULL
cytometric	NULL
analysis	NULL
.	NULL

Indirect	NULL
antibody	NULL
staining	NULL
and	NULL
flow	NULL
cytometric	NULL
analyses	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
43	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
10°	NULL
cells	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
Dulbecco	NULL
's	NULL
phosphate-buffered	NULL
saline	NULL
(	NULL
D-PBS	NULL
)	NULL
containing	NULL
2	NULL
%	NULL
FBS	NULL
and	NULL
0.1	NULL
%	NULL
sodium	NULL
azide	NULL
(	NULL
fluorescence-activated	NULL
cell	NULL
sorter	NULL
[	NULL
FACS	NULL
]	NULL
buffer	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
either	NULL
150	NULL
ng	NULL
of	NULL
UB2	NULL
(	NULL
Kaimaya	NULL
Biomedical	NULL
Co.	NULL
,	NULL
Tukwila	NULL
,	NULL
Wash.	NULL
)	NULL
or	NULL
isotype-matched	NULL
,	NULL
control	NULL
mouse	NULL
anti-human	NULL
immunoglobulin	NULL
G1	NULL
(	NULL
IgG1	NULL
)	NULL
antibodies	NULL
(	NULL
Sig-ma	NULL
)	NULL
at	NULL
4°C	NULL
for	NULL
30	NULL
min	NULL
.	NULL

Samples	NULL
were	NULL
washed	NULL
twice	NULL
in	NULL
FACS	NULL
buifer	NULL
,	NULL
and	NULL
phyco-erythrin-conjugated	NULL
goat	NULL
anti-mouse	NULL
IgG	NULL
secondary	NULL
antibodies	NULL
were	NULL
added	NULL
in	NULL
100	NULL
pl	NULL
of	NULL
FACS	NULL
buffer	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

Samples	NULL
were	NULL
washed	NULL
twice	NULL
with	NULL
FACS	NULL
buffer	NULL
,	NULL
fixed	NULL
overnight	NULL
in	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
paraformaldehyde	NULL
,	NULL
and	NULL
analyzed	NULL
with	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
and	NULL
Co.	NULL
,	NULL
Mountain	NULL
View	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Ten	NULL
thousand	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
each	NULL
sample	NULL
,	NULL
with	NULL
the	NULL
gate	NULL
set	NULL
to	NULL
exclude	NULL
dead	NULL
cells	NULL
and	NULL
debris	NULL
.	NULL

RNA	NULL
isolation	NULL
and	NULL
RPAs	NULL
.	NULL

At	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
,	NULL
P/I-treated	NULL
Jurkat	NULL
cells	NULL
were	NULL
pelleted	NULL
and	NULL
washed	NULL
once	NULL
in	NULL
D-PBS	NULL
.	NULL

Control	NULL
Jurkat	NULL
cells	NULL
were	NULL
similarly	NULL
cultured	NULL
but	NULL
were	NULL
not	NULL
treated	NULL
with	NULL
P/I	NULL
.	NULL

Total	NULL
RNA	NULL
from	NULL
10	NULL
``	NULL
cells	NULL
per	NULL
sample	NULL
was	NULL
extracted	NULL
with	NULL
the	NULL
RNeasy	NULL
kit	NULL
(	NULL
Qiagen	NULL
,	NULL
Chatsworth	NULL
,	NULL
Calif.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
,	NULL
and	NULL
RNase	NULL
protection	NULL
assays	NULL
(	NULL
RPA	NULL
)	NULL
were	NULL
performed	NULL
with	NULL
the	NULL
HybSpeed	NULL
RPA	NULL
kit	NULL
(	NULL
Ambion	NULL
,	NULL
Austin	NULL
,	NULL
Tex	NULL
.	NULL
)	NULL

.	NULL

Samples	NULL
(	NULL
25	NULL
pg	NULL
of	NULL
total	NULL
RNA	NULL
)	NULL
were	NULL
hybridized	NULL
to	NULL
a	NULL
riboprobe	NULL
spanning	NULL
Fas	NULL
exons	NULL
3	NULL
to	NULL
6	NULL
(	NULL
cDNA	NULL
sequence	NULL
510	NULL
to	NULL
750	NULL
)	NULL
and	NULL
a	NULL
control	NULL
glyceraldehyde-3-phosphate	NULL
dehydrogenase	NULL
(	NULL
GAPDH	NULL
)	NULL
riboprobe	NULL
.	NULL

Following	NULL
RNAse	NULL
digestion	NULL
,	NULL
protected	NULL
products	NULL
were	NULL
boiled	NULL
,	NULL
separated	NULL
by	NULL
electrophoresis	NULL
on	NULL
a	NULL
5	NULL
%	NULL
urea-polyacrylamide	NULL
gel	NULL
electrophoresis	NULL
(	NULL
PAGE	NULL
)	NULL
gel	NULL
,	NULL
and	NULL
analyzed	NULL
by	NULL
autoradiography	NULL
.	NULL

Scanning	NULL
densitometry	NULL
(	NULL
Molecular	NULL
Dynamics	NULL
,	NULL
Sunnyvale	NULL
,	NULL
Calif.	NULL
)	NULL
was	NULL
used	NULL
to	NULL
quantitate	NULL
the	NULL
fas	NULL
and	NULL
GAPDH	NULL
band	NULL
intensities	NULL
of	NULL
cach	NULL
sample	NULL
.	NULL

Relative	NULL
fold	NULL
induction	NULL
was	NULL
calculated	NULL
by	NULL
dividing	NULL
each	NULL
normalized	NULL
f2s/GAPDH	NULL
ratio	NULL
against	NULL
the	NULL
zero	NULL
time	NULL
point	NULL
.	NULL

Generation	NULL
of	NULL
fas	NULL
promoter	NULL
constructs	NULL
and	NULL
site-directed	NULL
mutagenesis	NULL
.	NULL

A	NULL
human	NULL
placental	NULL
genomic	NULL
phage	NULL
library	NULL
(	NULL
Clonetech	NULL
,	NULL
Palo	NULL
Alto	NULL
,	NULL
Calif.	NULL
)	NULL
was	NULL
screened	NULL
with	NULL
a	NULL
PCR-generated	NULL
,	NULL
[	NULL
a-*	NULL
``	NULL
P	NULL
]	NULL
dCTP-labeled	NULL
Fas	NULL
cDNA	NULL
probe	NULL
containing	NULL
5	NULL
'	NULL
untranslated	NULL
exon	NULL
1	NULL
and	NULL
2	NULL
sequences	NULL
:	NULL
forward	NULL
,	NULL
5	NULL
'	NULL
GGACCCGCTCAGTACGG	NULL
AGTT	NULL
;	NULL
reverse	NULL
,	NULL
5°	NULL
TTCACCTGGAGGACAGGGCTTATG	NULL
(	NULL
Life	NULL
Technolo-gies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
N.Y.	NULL
)	NULL
.	NULL

Plaque	NULL
hybridizations	NULL
were	NULL
carried	NULL
out	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
52	NULL
)	NULL
,	NULL
and	NULL
filters	NULL
were	NULL
washed	NULL
sequentially	NULL
in	NULL
6	NULL
%	NULL
SSC	NULL
(	NULL
0.9	NULL
M	NULL
NaCl	NULL
,	NULL
0.09	NULL
M	NULL
sodium	NULL
citrate	NULL
)	NULL
-0.1	NULL
%	NULL
sodium	NULL
dodecy	NULL
]	NULL
sulfate	NULL
(	NULL
SDS	NULL
)	NULL
at	NULL
42°C	NULL
for	NULL
20	NULL
min	NULL
,	NULL
2	NULL
%	NULL
SSC-0.1	NULL
%	NULL
SDS	NULL
at	NULL
60°C	NULL
for	NULL
20	NULL
min	NULL
,	NULL
and	NULL
1	NULL
%	NULL
SSC-0.1	NULL
%	NULL
SDS	NULL
for	NULL
20	NULL
min	NULL
before	NULL
autoradiography	NULL
.	NULL

Approximately	NULL
1.35	NULL
x	NULL
10°	NULL
plaques	NULL
were	NULL
screened	NULL
,	NULL
followed	NULL
by	NULL
sequential	NULL
hybridizations	NULL
of	NULL
the	NULL
positive	NULL
clones	NULL
.	NULL

Subsequent	NULL
subcloning	NULL
of	NULL
SacI	NULL
or	NULL
HindIII	NULL
inserts	NULL
into	NULL
pGEMI1Zf	NULL
(	NULL
+	NULL
)	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
Wis.	NULL
)	NULL
identified	NULL
a	NULL
2.16-kb	NULL
HindIII	NULL
fragment	NULL
containing	NULL
1.74	NULL
kb	NULL
proximal	NULL
to	NULL
the	NULL
Fas	NULL
translational	NULL
start	NULL
site	NULL
(	NULL
FasH3	NULL
)	NULL
.	NULL

Sanger	NULL
dideoxy	NULL
sequencing	NULL
(	NULL
U.S.	NULL
Biochemical	NULL
Corp.	NULL
,	NULL
Cleve-land	NULL
,	NULL
Ohio	NULL
)	NULL
confirmed	NULL
that	NULL
FasH3	NULL
contained	NULL
5	NULL
'	NULL
flanking	NULL
sequences	NULL
identical	NULL
to	NULL
those	NULL
previously	NULL
reported	NULL
for	NULL
human	NULL
fas	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Reporter	NULL
constructs	NULL
were	NULL
generated	NULL
with	NULL
the	NULL
2.16-kb	NULL
FasH3	NULL
fragment	NULL
and	NULL
primers	NULL
corresponding	NULL
to	NULL
sequences	NULL
-1739	NULL
to	NULL
-1717	NULL
(	NULL
5	NULL
'	NULL
AATAATCACTCAT	NULL
CTCACTGGGC	NULL
)	NULL
and	NULL
-43	NULL
to	NULL
-19	NULL
(	NULL
5°	NULL
CGAAGTGAAAGAGCITTCCCCAAC	NULL
TRANSCRIPTIONAL	NULL
REGULATION	NULL
OF	NULL
THE	NULL
HUMAN	NULL
frs	NULL
PROMOTER	NULL
-	NULL
2099	NULL
TC	NULL
)	NULL
by	NULL
PCR	NULL
to	NULL
generate	NULL
a	NULL
1.72-kb	NULL
product	NULL
.	NULL

This	NULL
PCR	NULL
product	NULL
was	NULL
then	NULL
subcloned	NULL
into	NULL
the	NULL
peR2	NULL
expression	NULL
vector	NULL
(	NULL
Invitrogen	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
Calif.	NULL
)	NULL
and	NULL
digested	NULL
with	NULL
EcoRI	NULL
,	NULL
and	NULL
the	NULL
insert	NULL
was	NULL
shuttled	NULL
into	NULL
pGEM7+	NULL
(	NULL
Promega	NULL
)	NULL
(	NULL
pFPR7+	NULL
)	NULL
.	NULL

A	NULL
partial	NULL
Xhol	NULL
digest	NULL
and	NULL
complete	NULL
HindIII	NULL
digest	NULL
of	NULL
pFPR7+	NULL
were	NULL
made	NULL
to	NULL
insert	NULL
the	NULL
1.7-kb	NULL
fragment	NULL
into	NULL
the	NULL
pGL2Basic	NULL
luciferase	NULL
reporter	NULL
construct	NULL
(	NULL
Promega	NULL
)	NULL
in	NULL
either	NULL
orientation	NULL
.	NULL

The	NULL
final	NULL
constructs	NULL
,	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
and	NULL
FPR1-Luc	NULL
(	NULL
-	NULL
)	NULL
,	NULL
spanning	NULL
the	NULL
region	NULL
(	NULL
1739	NULL
to	NULL
-19	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
fas	NULL
ATG	NULL
were	NULL
sequenced	NULL
to	NULL
verify	NULL
orientation	NULL
and	NULL
identity	NULL
.	NULL

The	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
reporter	NULL
construct	NULL
tk-Luc	NULL
was	NULL
generated	NULL
by	NULL
subcloning	NULL
the	NULL
Bg/II-HindIII	NULL
fragment	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
from	NULL
pRL-tk	NULL
(	NULL
Promega	NULL
)	NULL
into	NULL
pGEM-11	NULL
,	NULL
followed	NULL
by	NULL
insertion	NULL
of	NULL
the	NULL
Secl-Hind	NULL
[	NULL
II	NULL
fragment	NULL
into	NULL
pGL2B	NULL
.	NULL

The	NULL
A5/A6-tk-Luc	NULL
reporter	NULL
was	NULL
constructed	NULL
by	NULL
subcloning	NULL
the	NULL
Secl	NULL
fragment	NULL
from	NULL
FPR-Luc	NULL
(	NULL
+	NULL
)	NULL
into	NULL
tk-Luc	NULL
,	NULL
digesting	NULL
it	NULL
with	NULL
Xhol-Psfl	NULL
,	NULL
treating	NULL
it	NULL
with	NULL
a	NULL
Klenow	NULL
fragment	NULL
to	NULL
fill	NULL
recessed	NULL
ends	NULL
,	NULL
and	NULL
performing	NULL
blunt	NULL
end	NULL
ligation	NULL
.	NULL

Deletion	NULL
constructs	NULL
were	NULL
generated	NULL
as	NULL
follows	NULL
.	NULL

A5-Lue	NULL
(	NULL
-460	NULL
to	NULL
-19	NULL
)	NULL
is	NULL
the	NULL
product	NULL
of	NULL
a	NULL
religated	NULL
XhoI	NULL
digest	NULL
of	NULL
FPR-Luc	NULL
{	NULL
+	NULL
)	NULL
;	NULL
A6-Lue	NULL
(	NULL
-236	NULL
to	NULL
-19	NULL
)	NULL
is	NULL
the	NULL
product	NULL
of	NULL
a	NULL
religated	NULL
complete	NULL
SacI	NULL
digest	NULL
of	NULL
FPR-Luc	NULL
(	NULL
+	NULL
)	NULL
.	NULL

Constructs	NULL
within	NULL
the	NULL
A5-Luc	NULL
region	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
with	NULL
the	NULL
following	NULL
oligonucleotides	NULL
,	NULL
digested	NULL
with	NULL
KpnI	NULL
(	NULL
underlined	NULL
)	NULL
-HindIlI	NULL
(	NULL
double	NULL
underlined	NULL
)	NULL
,	NULL
and	NULL
subcloned	NULL
directly	NULL
into	NULL
pGL2B	NULL
:	NULL
A5.4+	NULL
(	NULL
5	NULL
)	NULL
GGGTACC-*°GCCACTGCAGGAACGCCC	NULL
CGGGACAG	NULL
)	NULL
;	NULL
A5.5+	NULL
(	NULL
5'GGGTACC	NULL
TACC	NULL
)	NULL
;	NULL
A5.7+	NULL
*°TCCCCAACCCGGGCGTTCCCCAGCG	NULL
)	NULL
;	NULL
A5.8+	NULL
_	NULL
(	NULL
5GGGTACC	NULL
``	NULL
°	NULL
GACCACCGGGGCTTTTCGTGAGCTCGTCT	NULL
)	NULL
;	NULL
FasRIH-	NULL
-	NULL
CGAAGTGAAAGAGCTTCCCCAAC	NULL
)	NULL
.	NULL

The	NULL
mutagenized	NULL
reporter	NULL
constructs	NULL
AS5M5.7-Luc	NULL
and	NULL
A5M5.8-Luc	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
with	NULL
the	NULL
appropriate	NULL
primers	NULL
(	NULL
A5.7M	NULL
,	NULL
5°CTCCCCAACCCittCG	NULL
TTCCCCAGCG	NULL
[	NULL
forward	NULL
]	NULL
and	NULL
5°CCTCGCTGGGGAACGaaaGGGTTGG	NULL
[	NULL
re-verse	NULL
}	NULL
;	NULL
A5.8M	NULL
,	NULL
5°CCGecyCTTITTCGTGAGCTCGTCT	NULL
[	NULL
forward	NULL
]	NULL
and	NULL
5'AGAC	NULL
GAGCTCACGAAAAGrggCGG	NULL
[	NULL
reverse	NULL
]	NULL
;	NULL
mutated	NULL
nucleotides	NULL
are	NULL
in	NULL
lower-case	NULL
)	NULL
by	NULL
using	NULL
the	NULL
QuikChange	NULL
site-directed	NULL
mutagenesis	NULL
kit	NULL
(	NULL
Stratagene	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
Calif.	NULL
)	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
recommendations	NULL
.	NULL

All	NULL
constructs	NULL
were	NULL
confirmed	NULL
by	NULL
dideoxy	NULL
sequencing	NULL
with	NULL
vector	NULL
and	NULL
internal	NULL
primers	NULL
.	NULL

Luciferase	NULL
reporters	NULL
containing	NULL
«	NULL
B-Sp1	NULL
concatemers	NULL
were	NULL
constructed	NULL
with	NULL
oligonucleotides	NULL
having	NULL
two	NULL
copies	NULL
of	NULL
the	NULL
element	NULL
at	NULL
position	NULL
-295	NULL
to	NULL
position	NULL
-286	NULL
.	NULL

These	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
either	NULL
KpnI	NULL
(	NULL
underlined	NULL
)	NULL
or	NULL
Sacl	NULL
(	NULL
double	NULL
underlined	NULL
)	NULL
3	NULL
'	NULL
overhangs	NULL
(	NULL
forward	NULL
,	NULL
5°CGGGCGTTCCCAAAAAG	NULL
GGCGTTCCCGAGCT	NULL
and	NULL
reverse	NULL
,	NULL
5CGGGAACGCCCITTITTTGGGAACG	NULL
CCCGGTAC	NULL
;	NULL
forward	NULL
,	NULL
5'CGGGCGTTCCCAAAAAGGGCGTTCCCGGTAC	NULL
and	NULL
reverse	NULL
,	NULL
5°CGGGAACGCCCTITTITTGGGAACGCCCGAGCT	NULL
}	NULL
.	NULL

The	NULL
corresponding	NULL
5°	NULL
KpnI-3	NULL
'	NULL
Sacl	NULL
or	NULL
5	NULL
``	NULL
Secl-3	NULL
'	NULL
KpnI	NULL
oligonucleotides	NULL
were	NULL
annealed	NULL
(	NULL
10	NULL
min	NULL
at	NULL
85°C	NULL
and	NULL
then	NULL
cooled	NULL
to	NULL
room	NULL
temperature	NULL
)	NULL
,	NULL
and	NULL
timed	NULL
ligations	NULL
were	NULL
prepared	NULL
with	NULL
T4	NULL
ligase	NULL
with	NULL
various	NULL
ratios	NULL
of	NULL
the	NULL
double-stranded	NULL
primers	NULL
.	NULL

Aliquots	NULL
of	NULL
the	NULL
reaction	NULL
mixtures	NULL
were	NULL
heated	NULL
to	NULL
75°C	NULL
for	NULL
10	NULL
min	NULL
to	NULL
inactivate	NULL
the	NULL
ligase	NULL
before	NULL
subcloning	NULL
into	NULL
the	NULL
KpnI-Sacl-digested	NULL
tk-Luc	NULL
vector	NULL
(	NULL
see	NULL
above	NULL
)	NULL
.	NULL

Various	NULL
clones	NULL
were	NULL
screened	NULL
by	NULL
sequence	NULL
analysis	NULL
to	NULL
determine	NULL
the	NULL
number	NULL
of	NULL
B-Sp1	NULL
elements	NULL
present	NULL
.	NULL

The	NULL
resultant	NULL
constructs	NULL
containing	NULL
two	NULL
,	NULL
four	NULL
,	NULL
and	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
kB-Sp1	NULL
site	NULL
were	NULL
used	NULL
for	NULL
transient	NULL
transfection	NULL
and	NULL
reporter	NULL
assays	NULL
.	NULL

Transient	NULL
transfections	NULL
and	NULL
reporter	NULL
assays	NULL
.	NULL

A	NULL
DEAE-dextran-chloroquine	NULL
mixture	NULL
was	NULL
used	NULL
for	NULL
transient	NULL
transfection	NULL
of	NULL
Jurkat	NULL
cells	NULL
.	NULL

Briefly	NULL
,	NULL
5	NULL
X	NULL
10°	NULL
to	NULL
7.5	NULL
X	NULL
10°	NULL
exponentially	NULL
growing	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
resuspended	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
transfection	NULL
solution	NULL
(	NULL
RPMI	NULL
plus	NULL
250	NULL
pg	NULL
of	NULL
DEAE-dextran	NULL
per	NULL
ml	NULL
,	NULL
0.1	NULL
M	NULL
Tris	NULL
[	NULL
pH	NULL
7.2	NULL
]	NULL
,	NULL
and	NULL
0.1	NULL
mM	NULL
chloroquine	NULL
)	NULL
together	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
reporter	NULL
construct	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
the	NULL
pRL-tk	NULL
Renilla	NULL
normalizing	NULL
luciferase	NULL
vector	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
37°C	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
plated	NULL
in	NULL
10	NULL
ml	NULL
of	NULL
complete	NULL
media	NULL
.	NULL

After	NULL
a	NULL
20-h	NULL
recovery	NULL
,	NULL
transfected	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
P/I	NULL
for	NULL
8	NULL
h.	NULL
Cell	NULL
extracts	NULL
and	NULL
luciferase	NULL
reagents	NULL
were	NULL
prepared	NULL
with	NULL
the	NULL
Promega	NULL
Dual-Lucif-erase	NULL
Reporter	NULL
Assay	NULL
System	NULL
.	NULL

Both	NULL
firefly	NULL
and	NULL
Renilla	NULL
luciferase	NULL
activities	NULL
were	NULL
monitored	NULL
with	NULL
a	NULL
luminometer	NULL
(	NULL
Turner	NULL
Industries	NULL
,	NULL
Sunnyvale	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

Normalized	NULL
reporter	NULL
activity	NULL
is	NULL
expressed	NULL
as	NULL
the	NULL
firefly	NULL
luciferase	NULL
value	NULL
divided	NULL
by	NULL
the	NULL
Renilla	NULL
luciferase	NULL
value	NULL
.	NULL

Relative	NULL
fold	NULL
induction	NULL
is	NULL
calculated	NULL
as	NULL
the	NULL
normalized	NULL
reporter	NULL
activity	NULL
of	NULL
the	NULL
test	NULL
sample	NULL
divided	NULL
by	NULL
either	NULL
the	NULL
untreated	NULL
FPR-Luc	NULL
or	NULL
A5-Luc	NULL
reporter	NULL
construct	NULL
,	NULL
as	NULL
indicated	NULL
below	NULL
.	NULL

The	NULL
Rous	NULL
sarcoma	NULL
virus	NULL
promoter-driven	NULL
IxBa	NULL
construct	NULL
(	NULL
RSV-IxBa	NULL
)	NULL
and	NULL
vector	NULL
control	NULL
were	NULL
obtained	NULL
from	NULL
Tse-Wa	NULL
Tan	NULL
(	NULL
Baylor	NULL
College	NULL
of	NULL
Medicine	NULL
,	NULL
Houston	NULL
,	NULL
Tex	NULL
.	NULL
)	NULL

.	NULL

Nuclear	NULL
extract	NULL
preparation	NULL
,	NULL
EMSAs	NULL
,	NULL
supershift	NULL
analyses	NULL
,	NULL
and	NULL
displacement	NULL
studies	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
a	NULL
modified	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
15	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
7.5	NULL
X	NULL
10°	NULL
Jurkat	NULL
cells	NULL
were	NULL
washed	NULL
in	NULL
PBS	NULL
and	NULL
pelleted	NULL
before	NULL
resuspension	NULL
in	NULL
200	NULL
l	NULL
of	NULL
cold	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
0.1	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
[	NULL
PMSF	NULL
]	NULL
)	NULL
and	NULL
incubated	NULL
for	NULL
20	NULL
min	NULL
on	NULL
ice	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
200	NULL
ul	NULL
of	NULL
cold	NULL
buffer	NULL
B	NULL
(	NULL
buffer	NULL
A	NULL
with	NULL
0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
gently	NULL
pipetted	NULL
and	NULL
returned	NULL
on	NULL
ice	NULL
for	NULL
another	NULL
20	NULL
min	NULL
.	NULL

Nuclei	NULL
were	NULL
pelleted	NULL
(	NULL
5,000	NULL
x	NULL
g	NULL
,	NULL
2	NULL
min	NULL
)	NULL
,	NULL
washed	NULL
in	NULL
buffer	NULL
A	NULL
,	NULL
and	NULL
pelleted	NULL
again	NULL
,	NULL
and	NULL
nuclear	NULL
proteins	NULL
were	NULL
extracted	NULL
in	NULL
25	NULL
ul	NULL
of	NULL
buffer	NULL
D	NULL
(	NULL
400	NULL
mM	NULL
NaCl	NULL
,	NULL
20	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
EGTA	NULL
,	NULL
1	NULL
mM	NULL
dithiothreitol	NULL
1	NULL
mM	NULL
PMSF	NULL
)	NULL
.	NULL

The	NULL
tubes	NULL
were	NULL
iced	NULL
for	NULL
at	NULL
least	NULL
30	NULL
min	NULL
,	NULL
followed	NULL
by	NULL
centrifugation	NULL
at	NULL
4°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
recov-ered	NULL
,	NULL
snap-frozen	NULL
in	NULL
liquid	NULL
nitrogen	NULL
,	NULL
and	NULL
stored	NULL
at	NULL
-80°C	NULL
prior	NULL
to	NULL
use	NULL
.	NULL

Probes	NULL
used	NULL
for	NULL
EMSAs	NULL
were	NULL
radiolabeled	NULL
by	NULL
[	NULL
y-P	NULL
]	NULL
ATP	NULL
end	NULL
labeling	NULL
with	NULL
T4	NULL
polynucleotide	NULL
kinase	NULL
.	NULL

Briefly	NULL
,	NULL
30	NULL
pg	NULL
of	NULL
the	NULL
A5-Luc	NULL
plasmid	NULL
was	NULL
digested	NULL
with	NULL
Xhol	NULL
,	NULL
dephosphorylated	NULL
with	NULL
calf	NULL
intestine	NULL
phosphatase	NULL
,	NULL
and	NULL
both	NULL
enzymes	NULL
were	NULL
inactivated	NULL
at	NULL
85°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

An	NULL
aliquot	NULL
of	NULL
the	NULL
digest	NULL
(	NULL
7.5	NULL
mg	NULL
)	NULL
was	NULL
end	NULL
labeled	NULL
2100	NULL
CHAN	NULL
ET	NULL
AL	NULL
.	NULL

with	NULL
[	NULL
y-	NULL
>	NULL
°P	NULL
]	NULL
ATP	NULL
for	NULL
60	NULL
min	NULL
before	NULL
the	NULL
kinase	NULL
was	NULL
inactivated	NULL
at	NULL
75°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

The	NULL
end-labeled	NULL
plasmid	NULL
was	NULL
then	NULL
digested	NULL
overnight	NULL
with	NULL
Seel	NULL
,	NULL
and	NULL
the	NULL
released	NULL
probe	NULL
A	NULL
(	NULL
-460	NULL
to	NULL
-236	NULL
)	NULL
was	NULL
gel	NULL
purified	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
11	NULL
)	NULL
.	NULL

The	NULL
oligonucleotide	NULL
probe	NULL
B	NULL
(	NULL
-306	NULL
to	NULL
-278	NULL
;	NULL
5'~**°CTCCCCAACCCGGGCGTTC	NULL
CCCAGCGAGG	NULL
)	NULL
or	NULL
its	NULL
mutated	NULL
counterpart	NULL
was	NULL
annealed	NULL
to	NULL
the	NULL
corresponding	NULL
complementary	NULL
sequence	NULL
before	NULL
1	NULL
pmol	NULL
was	NULL
end	NULL
labeled	NULL
with	NULL
[	NULL
y-*°P	NULL
]	NULL
ATP	NULL
for	NULL
30	NULL
min	NULL
.	NULL

The	NULL
labeled	NULL
probe	NULL
was	NULL
purified	NULL
from	NULL
unincorporated	NULL
nucleotides	NULL
by	NULL
using	NULL
a	NULL
Chroma	NULL
Spin	NULL
10	NULL
column	NULL
(	NULL
Clonetech	NULL
)	NULL
following	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
.	NULL

The	NULL
specific	NULL
activities	NULL
of	NULL
all	NULL
``	NULL
P-labeled	NULL
oligoprobes	NULL
were	NULL
routinely	NULL
5	NULL
X	NULL
10°	NULL
to	NULL
6	NULL
x	NULL
10°	NULL
cpm	NULL
per	NULL
pmol	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
determined	NULL
with	NULL
the	NULL
Bio-Rad	NULL
protein	NULL
assay	NULL
reagent	NULL
(	NULL
Bio-Rad	NULL
,	NULL
Richmond	NULL
,	NULL
Calif.	NULL
)	NULL
.	NULL

For	NULL
EMSAs	NULL
,	NULL
6	NULL
pg	NULL
of	NULL
nuclear	NULL
extract	NULL
was	NULL
incubated	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
19	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
[	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
Tris	NULL
(	NULL
pH	NULL
7.9	NULL
)	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mg	NULL
of	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
,	NULL
and	NULL
5	NULL
%	NULL
glycerol	NULL
]	NULL
for	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
before	NULL
50,000	NULL
cpm	NULL
of	NULL
the	NULL
indicated	NULL
y-*	NULL
``	NULL
P-end-labeled	NULL
probe	NULL
was	NULL
added	NULL
for	NULL
another	NULL
15	NULL
min	NULL
.	NULL

For	NULL
competition	NULL
assays	NULL
,	NULL
excess	NULL
unlabeled	NULL
oligonucleotides	NULL
were	NULL
preincubated	NULL
for	NULL
15	NULL
min	NULL
prior	NULL
to	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probe	NULL
(	NULL
50,000	NULL
cpm	NULL
)	NULL
.	NULL

For	NULL
antibody-mediated	NULL
supershift	NULL
assays	NULL
,	NULL
extracts	NULL
were	NULL
preincubated	NULL
with	NULL
1	NULL
pl	NULL
of	NULL
either	NULL
anti-p50	NULL
,	NULL
-p65	NULL
,	NULL
-c-Rel	NULL
(	NULL
Oncogene	NULL
Research	NULL
,	NULL
Cam-bridge	NULL
,	NULL
Mass	NULL
.	NULL
)	NULL

-relB	NULL
,	NULL
-p52	NULL
,	NULL
or	NULL
-Sp1	NULL
(	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
,	NULL
Santa	NULL
Cruz	NULL
,	NULL
Calif.	NULL
)	NULL
antibodies	NULL
at	NULL
4°C	NULL
for	NULL
45	NULL
min	NULL
before	NULL
the	NULL
addition	NULL
of	NULL
the	NULL
radiolabeled	NULL
probe	NULL
.	NULL

The	NULL
reactions	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
4.5	NULL
%	NULL
polyacrylamide	NULL
nondenaturing	NULL
PAGE	NULL
gel	NULL
in	NULL
0.5	NULL
%	NULL
Tris-borate-EDTA	NULL
electrophoresed	NULL
for	NULL
2.5	NULL
h	NULL
at	NULL
100	NULL
V	NULL
before	NULL
drying	NULL
and	NULL
exposed	NULL
to	NULL
autoradiographic	NULL
film	NULL
.	NULL

For	NULL
displacement	NULL
studies	NULL
,	NULL
4	NULL
footprinting	NULL
units	NULL
(	NULL
fpu	NULL
)	NULL
of	NULL
Sp1	NULL
(	NULL
~30	NULL
ng	NULL
;	NULL
Promega	NULL
)	NULL
was	NULL
preincubated	NULL
in	NULL
a	NULL
total	NULL
volume	NULL
of	NULL
19	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
for	NULL
5	NULL
min	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
12,500	NULL
cpm	NULL
of	NULL
labeled	NULL
probe	NULL
B	NULL
.	NULL

After	NULL
15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
increasing	NULL
amounts	NULL
of	NULL
recombinant	NULL
p50	NULL
NF-	NULL
«	NULL
B	NULL
(	NULL
Promega	NULL
)	NULL
subunits	NULL
were	NULL
added	NULL
for	NULL
an	NULL
additional	NULL
15	NULL
min	NULL
before	NULL
the	NULL
mixture	NULL
was	NULL
loaded	NULL
on	NULL
a	NULL
4.5	NULL
%	NULL
polyacrylamide	NULL
PAGE	NULL
gel	NULL
as	NULL
described	NULL
above	NULL
.	NULL

RESULTS	NULL
Expression	NULL
of	NULL
Fas	NULL
mRNA	NULL
and	NULL
protein	NULL
is	NULL
upregulated	NULL
in	NULL
Jurkat	NULL
cells	NULL
by	NULL
pharmacological	NULL
agents	NULL
that	NULL
mimic	NULL
T-cell	NULL
activation	NULL
.	NULL

While	NULL
resting	NULL
T	NULL
cells	NULL
express	NULL
low	NULL
to	NULL
undetectable	NULL
levels	NULL
of	NULL
the	NULL
Fas	NULL
protein	NULL
(	NULL
26	NULL
,	NULL
37	NULL
,	NULL
41	NULL
,	NULL
44	NULL
)	NULL
,	NULL
it	NULL
is	NULL
rapidly	NULL
upregulated	NULL
upon	NULL
exposure	NULL
to	NULL
specific	NULL
antigens	NULL
,	NULL
mitogens	NULL
,	NULL
cytokines	NULL
,	NULL
TCR	NULL
antibodies	NULL
,	NULL
and	NULL
various	NULL
pharmacological	NULL
agents	NULL
such	NULL
as	NULL
P/I	NULL
(	NULL
6	NULL
,	NULL
37	NULL
,	NULL
44	NULL
)	NULL
.	NULL

The	NULL
Jurkat	NULL
T-cell	NULL
line	NULL
has	NULL
an	NULL
activated	NULL
T-cell	NULL
phenotype	NULL
,	NULL
in	NULL
that	NULL
it	NULL
constitutively	NULL
expresses	NULL
cell	NULL
surface	NULL
Fas	NULL
(	NULL
Fig	NULL
.	NULL

1A	NULL
)	NULL
.	NULL

Because	NULL
we	NULL
were	NULL
interested	NULL
in	NULL
the	NULL
transcriptional	NULL
mechanisms	NULL
controlling	NULL
Fas	NULL
expression	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
Fas	NULL
could	NULL
be	NULL
upregulated	NULL
in	NULL
Jurkat	NULL
cells	NULL
upon	NULL
activation	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
P/I	NULL
for	NULL
various	NULL
times	NULL
,	NULL
and	NULL
mRNA	NULL
and	NULL
protein	NULL
expression	NULL
was	NULL
determined	NULL
with	NULL
RPAs	NULL
and	NULL
FACS	NULL
analyses	NULL
,	NULL
respectively	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1A	NULL
,	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
upregulated	NULL
surface	NULL
Fas	NULL
after	NULL
P/I	NULL
stimulation	NULL
.	NULL

Increased	NULL
Fas	NULL
was	NULL
detectable	NULL
as	NULL
early	NULL
as	NULL
4	NULL
h	NULL
poststimulation	NULL
,	NULL
reached	NULL
maximal	NULL
levels	NULL
by	NULL
8	NULL
h	NULL
,	NULL
and	NULL
declined	NULL
to	NULL
near-baseline	NULL
levels	NULL
by	NULL
24	NULL
h.	NULL
A	NULL
1.5-	NULL
to	NULL
2.0-fold	NULL
increase	NULL
in	NULL
both	NULL
the	NULL
percentage	NULL
of	NULL
cells	NULL
expressing	NULL
Fas	NULL
as	NULL
well	NULL
as	NULL
the	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
(	NULL
MFT	NULL
)	NULL
,	NULL
representative	NULL
of	NULL
antigenic	NULL
density	NULL
on	NULL
a	NULL
per-cell	NULL
basis	NULL
,	NULL
was	NULL
observed	NULL
.	NULL

Correspondingly	NULL
,	NULL
as	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1B	NULL
,	NULL
Fas	NULL
mRNA	NULL
levels	NULL
were	NULL
upregulated	NULL
by	NULL
10-fold	NULL
in	NULL
Jurkat	NULL
cells	NULL
activated	NULL
for	NULL
2	NULL
h	NULL
;	NULL
mRNA	NULL
levels	NULL
declined	NULL
subsequently	NULL
over	NULL
the	NULL
time	NULL
period	NULL
examined	NULL
(	NULL
24	NULL
h	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
an	NULL
immediate-early	NULL
,	NULL
activation-dependent	NULL
upregulation	NULL
of	NULL
Fas	NULL
in	NULL
P/I-stimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
suggesting	NULL
a	NULL
likely	NULL
transcriptional	NULL
control	NULL
.	NULL

A	NULL
220-bp	NULL
region	NULL
in	NULL
the	NULL
Fas	NULL
promoter	NULL
is	NULL
required	NULL
for	NULL
activation-dependent	NULL
upregulation	NULL
.	NULL

To	NULL
test	NULL
the	NULL
premise	NULL
that	NULL
activation-dependent	NULL
Fas	NULL
upregulation	NULL
was	NULL
modulated	NULL
at	NULL
the	NULL
level	NULL
of	NULL
transcription	NULL
,	NULL
approximately	NULL
1.7	NULL
kb	NULL
of	NULL
the	NULL
5	NULL
'	NULL
region	NULL
flanking	NULL
the	NULL
fas	NULL
translational	NULL
start	NULL
site	NULL
(	NULL
nucleotides	NULL
-1739	NULL
to	NULL
-19	NULL
)	NULL
were	NULL
isolated	NULL
from	NULL
a	NULL
human	NULL
placental	NULL
genomic	NULL
library	NULL
and	NULL
subcloned	NULL
into	NULL
the	NULL
pGL2-Basic	NULL
luciferase	NULL
reporter	NULL
vector	NULL
in	NULL
both	NULL
orientations	NULL
relative	NULL
to	NULL
the	NULL
luciferase	NULL
gene	NULL
.	NULL

The	NULL
basal	NULL
activity	NULL
of	NULL
the	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
construct	NULL
was	NULL
first	NULL
determined	NULL
by	NULL
transient	NULL
transfections	NULL
into	NULL
various	NULL
T-	NULL
and	NULL
B-cell	NULL
lines	NULL
,	NULL
followed	NULL
by	NULL
extract	NULL
preparations	NULL
and	NULL
luciferase	NULL
activity	NULL
measurements	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2A	NULL
,	NULL
the	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
construct	NULL
demonstrated	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

%	NULL
Fas	NULL
+	NULL
MFI	NULL
Isotype-matched	NULL
Control	NULL
49.9	NULL
2.88	NULL
ID	NULL
5	NULL
60.6	NULL
2.97	NULL
[	NULL
e	NULL
]	NULL
h	NULL
€	NULL
91.2	NULL
4.32	NULL
2	NULL
58.3	NULL
3.13	NULL
Log	NULL
Fluorescence	NULL
Intensity	NULL
Untreated	NULL
P	NULL
/I	NULL
Time	NULL
(	NULL
Hrs	NULL
)	NULL
:	NULL
0	NULL
8	NULL
24	NULL
2	NULL
4	NULL
8	NULL
24	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
@	NULL
s	NULL
-	NULL
0	NULL
0	NULL
0	NULL
®	NULL
GAPDH	NULL
|No	NULL
|	NULL
mee	NULL
.	NULL

cae	NULL
.	NULL

sass	NULL
.	NULL

ses	NULL
.	NULL

mame	NULL
Normalized	NULL
Fas/GAPDH	NULL
ratio	NULL
:	NULL
|	NULL
3.5	NULL
|	NULL
6.4	NULL
|	NULL
8.1	NULL
|	NULL
35.0|	NULL
20.6	NULL
)	NULL
20.9|11.9	NULL
Relative	NULL
Fold	NULL
Induction	NULL
:	NULL
|	NULL
1.0	NULL
|	NULL
1.8	NULL
|	NULL
2.3	NULL
|	NULL
10.0|	NULL
5.9	NULL
|	NULL
6.0	NULL
|	NULL
3.4	NULL
FIG	NULL
.	NULL

1	NULL
.	NULL

Time	NULL
course	NULL
induction	NULL
of	NULL
Fas	NULL
upregulation	NULL
in	NULL
P/I-treated	NULL
Jurkat	NULL
cells	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Cells	NULL
were	NULL
harvested	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
,	NULL
and	NULL
Fas	NULL
expression	NULL
was	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

Isotype-matched	NULL
control	NULL
antibody	NULL
staining	NULL
is	NULL
represented	NULL
as	NULL
a	NULL
dashed	NULL
line	NULL
,	NULL
and	NULL
Fas	NULL
staining	NULL
is	NULL
represented	NULL
as	NULL
solid	NULL
lines	NULL
.	NULL

The	NULL
percentage	NULL
of	NULL
specific	NULL
Fas	NULL
staining	NULL
and	NULL
the	NULL
mean	NULL
fluorescence	NULL
intensity	NULL
(	NULL
MFT	NULL
)	NULL
of	NULL
Jurkat	NULL
cells	NULL
at	NULL
each	NULL
time	NULL
point	NULL
are	NULL
shown	NULL
to	NULL
the	NULL
right	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Cells	NULL
were	NULL
harvested	NULL
at	NULL
the	NULL
indicated	NULL
time	NULL
,	NULL
total	NULL
RNA	NULL
was	NULL
isolated	NULL
,	NULL
and	NULL
Fas	NULL
mRNA	NULL
accumulation	NULL
was	NULL
determined	NULL
by	NULL
RNAse	NULL
protection	NULL
analysis	NULL
.	NULL

Scanning	NULL
densitometry	NULL
was	NULL
used	NULL
to	NULL
normalize	NULL
Fas	NULL
mRNA	NULL
levels	NULL
and	NULL
to	NULL
calculate	NULL
the	NULL
relative	NULL
fold	NULL
induction	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
untreated	NULL
,	NULL
time	NULL
zero	NULL
sample	NULL
.	NULL

basal	NULL
activity	NULL
in	NULL
the	NULL
Jurkat	NULL
(	NULL
13-fold	NULL
over	NULL
empty	NULL
vector	NULL
)	NULL
,	NULL
Molt-4	NULL
(	NULL
32-fold	NULL
)	NULL
,	NULL
and	NULL
HSB	NULL
(	NULL
14-fold	NULL
)	NULL
T-cell	NULL
lines	NULL
.	NULL

In	NULL
B-cell	NULL
lines	NULL
,	NULL
modest	NULL
basal	NULL
activity	NULL
was	NULL
observed	NULL
only	NULL
in	NULL
Raji	NULL
cells	NULL
(	NULL
fivefold	NULL
over	NULL
empty	NULL
vector	NULL
alone	NULL
)	NULL
,	NULL
but	NULL
not	NULL
in	NULL
Daudi	NULL
or	NULL
Ramos	NULL
cells	NULL
.	NULL

These	NULL
results	NULL
document	NULL
that	NULL
the	NULL
1.7-kb	NULL
region	NULL
upstream	NULL
of	NULL
the	NULL
fas	NULL
ATG	NULL
contains	NULL
a	NULL
functional	NULL
promoter	NULL
operative	NULL
in	NULL
T-cell	NULL
lines	NULL
and	NULL
certain	NULL
B-cell	NULL
lines	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
was	NULL
responsive	NULL
to	NULL
activation	NULL
,	NULL
transiently	NULL
transfected	NULL
Jurkat	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
P/I	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
,	NULL
and	NULL
the	NULL
relative	NULL
luciferase	NULL
activities	NULL
of	NULL
untreated	NULL
and	NULL
P/I-stimulated	NULL
cells	NULL
were	NULL
compared	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
activity	NULL
increased	NULL
approximately	NULL
17-fold	NULL
in	NULL
response	NULL
to	NULL
P/I	NULL
treatment	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
[	NULL
4	NULL
]	NULL
~1739	NULL
CJ	NULL
perss	NULL
B	NULL
FPR-Luc	NULL
(	NULL
+	NULL
)	NULL
30	NULL
N	NULL
&	NULL
ae	NULL
o	NULL
>	NULL
.	NULL

£2	NULL
3	NULL
5	NULL
p	NULL
<	NULL
I	NULL
k=	NULL
o	NULL
.	NULL

o	NULL
2	NULL
S	NULL
©	NULL
d	NULL
[	NULL
€	NULL
]	NULL
P/I	NULL
(	NULL
Hrs	NULL
)	NULL
Jurkat	NULL
Molt4	NULL
HSB	NULL
_	NULL
Raji	NULL
Daudi	NULL
Ramos	NULL
Competitor	NULL
None	NULL
Sp1	NULL
xB	NULL
AP-	NULL
<	NULL
-	NULL
C2	NULL
-m	NULL
*-	NULL
C1	NULL
-	NULL
»	NULL
«	NULL
-	NULL
NS	NULL
.	NULL

-p	NULL
Probe	NULL
A	NULL
:	NULL
-460	NULL
/	NULL
-236	NULL
compared	NULL
to	NULL
the	NULL
basal	NULL
activity	NULL
of	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
.	NULL

The	NULL
fas	NULL
promoter	NULL
is	NULL
orientation	NULL
dependent	NULL
,	NULL
since	NULL
FPR1-Luc	NULL
(	NULL
-	NULL
)	NULL
was	NULL
inactive	NULL
in	NULL
both	NULL
resting	NULL
and	NULL
stimulated	NULL
cells	NULL
.	NULL

To	NULL
more	NULL
precisely	NULL
map	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
(	NULL
s	NULL
)	NULL
responsive	NULL
to	NULL
P/I	NULL
activation	NULL
,	NULL
two	NULL
deletion	NULL
constructs	NULL
containing	NULL
the	NULL
sequences	NULL
from	NULL
-460	NULL
to	NULL
-19	NULL
(	NULL
AS-Luc	NULL
)	NULL
and	NULL
-240	NULL
to	NULL
-19	NULL
(	NULL
A6-Luc	NULL
)	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
in	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
P/I	NULL
inducibility	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
was	NULL
maintained	NULL
when	NULL
the	NULL
sequences	NULL
between	NULL
-1739	NULL
and	NULL
-460	NULL
were	NULL
deleted	NULL
.	NULL

However	NULL
,	NULL
when	NULL
sequences	NULL
between	NULL
-460	NULL
and	NULL
-240	NULL
were	NULL
deleted	NULL
,	NULL
P/I-induced	NULL
upregulation	NULL
was	NULL
virtually	NULL
absent	NULL
.	NULL

As	NULL
shown	NULL
,	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
and	NULL
A5S-Luc	NULL
were	NULL
upregulated	NULL
17-	NULL
and	NULL
15-fold	NULL
after	NULL
P/I	NULL
treatment	NULL
,	NULL
respectively	NULL
,	NULL
while	NULL
the	NULL
A6-Luc	NULL
construct	NULL
was	NULL
upregulated	NULL
by	NULL
less	NULL
than	NULL
4-fold	NULL
.	NULL

Interestingly	NULL
,	NULL
no	NULL
differences	NULL
were	NULL
noted	NULL
in	NULL
the	NULL
activity	NULL
of	NULL
these	NULL
constructs	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
suggesting	NULL
that	NULL
the	NULL
fas	NULL
promoter	NULL
sequences	NULL
between	NULL
-460	NULL
and	NULL
-240	NULL
are	NULL
critically	NULL
important	NULL
for	NULL
activation-dependent	NULL
,	NULL
but	NULL
not	NULL
basal	NULL
,	NULL
transcription	NULL
.	NULL

Sequence	NULL
analysis	NULL
within	NULL
this	NULL
region	NULL
demonstrated	NULL
the	NULL
presence	NULL
of	NULL
consensus	NULL
elements	NULL
for	NULL
several	NULL
transcription	NULL
factors	NULL
,	NULL
including	NULL
AP-2	NULL
,	NULL
GAS	NULL
,	NULL
NF-kB	NULL
,	NULL
and	NULL
NF-AT	NULL
.	NULL

To	NULL
investigate	NULL
whether	NULL
the	NULL
220-bp	NULL
region	NULL
between	NULL
-460	NULL
and	NULL
-240	NULL
contained	NULL
enhancer	NULL
elements	NULL
responsive	NULL
to	NULL
P/I	NULL
activation	NULL
,	NULL
this	NULL
region	NULL
was	NULL
subcloned	NULL
proximal	NULL
to	NULL
a	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
in	NULL
a	NULL
luciferase	NULL
reporter	NULL
construct	NULL
(	NULL
AS/A6-tk-Luc	NULL
)	NULL
,	NULL
and	NULL
transient	NULL
transfection	NULL
reporter	NULL
assays	NULL
were	NULL
carried	NULL
out	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

2B	NULL
,	NULL
the	NULL
AS/A6-tk-Lue	NULL
construct	NULL
was	NULL
highly	NULL
inducible	NULL
by	NULL
P/I	NULL
(	NULL
12-fold	NULL
relative	NULL
to	NULL
tk-Luc	NULL
)	NULL
,	NULL
at	NULL
levels	NULL
comparable	NULL
to	NULL
that	NULL
of	NULL
the	NULL
native	NULL
Fas	NULL
promoter	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
between	NULL
-460	NULL
and	NULL
-240	NULL
contains	NULL
enhancer	NULL
element	NULL
(	NULL
s	NULL
)	NULL
necessary	NULL
for	NULL
activation	NULL
responsiveness	NULL
.	NULL

TRANSCRIPTIONAL	NULL
REGULATION	NULL
OF	NULL
THE	NULL
HUMAN	NULL
f	NULL
@	NULL
s	NULL
PROMOTER	NULL
-	NULL
2101	NULL
FPR1	NULL
-	NULL
Lue	NULL
(	NULL
+	NULL
)	NULL
~19	NULL
19	NULL
FPR1	NULL
-	NULL
Lue	NULL
(	NULL
-	NULL
)	NULL
1739	NULL
~460	NULL
A5	NULL
-	NULL
Lue	NULL
19	NULL
24°	NULL
-	NULL
[	NULL
lue	NULL
]	NULL
A6	NULL
-	NULL
Luc	NULL
+19	NULL
tk	NULL
-	NULL
Lue	NULL
[	NULL
-	NULL
]	NULL
None	NULL
BB	NULL
pa	NULL
0	NULL
5	NULL
10	NULL
15	NULL
20	NULL
A5/A6	NULL
«	NULL
tk	NULL
-	NULL
Luc	NULL
Relative	NULL
Fold	NULL
Induction	NULL
FIG	NULL
.	NULL

2	NULL
.	NULL

Basal	NULL
and	NULL
inducible	NULL
fas	NULL
promoter	NULL
activity	NULL
and	NULL
in	NULL
vitro	NULL
EMSA	NULL
analysis	NULL
.	NULL

(	NULL
A	NULL
)	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
containing	NULL
the	NULL
sequence	NULL
from	NULL
-1739	NULL
to	NULL
-19	NULL
is	NULL
active	NULL
in	NULL
T-cell	NULL
lines	NULL
and	NULL
the	NULL
B-lymphocyte	NULL
line	NULL
Raji	NULL
,	NULL
but	NULL
inactive	NULL
in	NULL
Daudi	NULL
or	NULL
Ramos	NULL
cells	NULL
.	NULL

Cells	NULL
were	NULL
transfected	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
either	NULL
the	NULL
empty	NULL
reporter	NULL
(	NULL
pGL2B	NULL
[	NULL
D	NULL
]	NULL
)	NULL
or	NULL
the	NULL
fas	NULL
promoter	NULL
reporter	NULL
vector	NULL
(	NULL
FPR1-Luc	NULL
[	NULL
MI	NULL
]	NULL
)	NULL
;	NULL
10	NULL
ng	NULL
of	NULL
pRL-tk	NULL
vector	NULL
was	NULL
cotransfected	NULL
for	NULL
normalization	NULL
.	NULL

Extracts	NULL
were	NULL
taken	NULL
after	NULL
40	NULL
h	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

Relative	NULL
fold	NULL
activity	NULL
was	NULL
calculated	NULL
as	NULL
the	NULL
normalized	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
activity	NULL
divided	NULL
by	NULL
the	NULL
normalized	NULL
pGL2B	NULL
value	NULL
.	NULL

(	NULL
B	NULL
)	NULL
fas	NULL
promoter	NULL
sequences	NULL
-460	NULL
to	NULL
-240	NULL
are	NULL
required	NULL
for	NULL
inducible	NULL
fas	NULL
reporter	NULL
activity	NULL
.	NULL

FPR1-Luc	NULL
in	NULL
both	NULL
orientations	NULL
(	NULL
forward	NULL
and	NULL
reverse	NULL
)	NULL
,	NULL
A5-Luc	NULL
,	NULL
A6-Luc	NULL
,	NULL
tk-Lue	NULL
,	NULL
and	NULL
A5/A6-tk-Lue	NULL
constructs	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
pRL-tk	NULL
for	NULL
normalization	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
then	NULL
left	NULL
untreated	NULL
(	NULL
C	NULL
)	NULL
or	NULL
were	NULL
activated	NULL
with	NULL
P/I	NULL
(	NULL
I	NULL
)	NULL
for	NULL
8	NULL
h	NULL
before	NULL
harvesting	NULL
of	NULL
the	NULL
extracts	NULL
for	NULL
measurement	NULL
of	NULL
luciferase	NULL
activity	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
averages	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
(	NULL
+	NULL
standard	NULL
deviation	NULL
)	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
relative	NULL
fold	NULL
induction	NULL
over	NULL
normalized	NULL
luciferase	NULL
values	NULL
from	NULL
untreated	NULL
Jurkat	NULL
cells	NULL
containing	NULL
FPR1-Luc	NULL
(	NULL
+	NULL
)	NULL
.	NULL

For	NULL
tk-Luc	NULL
and	NULL
A5/A6-tk-Luc	NULL
,	NULL
the	NULL
relative	NULL
fold	NULL
induction	NULL
was	NULL
calculated	NULL
separately	NULL
as	NULL
the	NULL
normalized	NULL
luciferase	NULL
value	NULL
divided	NULL
by	NULL
the	NULL
untreated	NULL
,	NULL
normalized	NULL
tk-Luc	NULL
luciferase	NULL
value	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Specific	NULL
protein	NULL
complexes	NULL
bind	NULL
the	NULL
enhancer	NULL
region	NULL
between	NULL
-460	NULL
and	NULL
-236	NULL
.	NULL

*°P-labeled	NULL
probe	NULL
A	NULL
(	NULL
50,000	NULL
cpm	NULL
)	NULL
was	NULL
mixed	NULL
with	NULL
nuclear	NULL
extracts	NULL
from	NULL
untreated	NULL
or	NULL
P/l-activated	NULL
Jurkat	NULL
cells	NULL
(	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
.	NULL

Specific	NULL
complexes	NULL
(	NULL
C1	NULL
and	NULL
C2	NULL
)	NULL
are	NULL
indicated	NULL
.	NULL

N.S	NULL
.	NULL

,	NULL
nonspecific	NULL
complexes	NULL
.	NULL

Cold	NULL
competition	NULL
mixtures	NULL
with	NULL
a	NULL
25-fold	NULL
excess	NULL
of	NULL
the	NULL
indicated	NULL
consensus	NULL
elements	NULL
(	NULL
right	NULL
panel	NULL
,	NULL
lanes	NULL
4	NULL
to	NULL
7	NULL
)	NULL
were	NULL
mixed	NULL
with	NULL
extracts	NULL
from	NULL
Jurkat	NULL
cells	NULL
activated	NULL
with	NULL
P/I	NULL
for	NULL
1	NULL
h	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
labeled	NULL
probe	NULL
A	NULL
.	NULL

To	NULL
analyze	NULL
whether	NULL
transcription	NULL
factors	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
activation-dependent	NULL
upregulation	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
within	NULL
this	NULL
region	NULL
,	NULL
EMSA	NULL
analyses	NULL
were	NULL
carried	NULL
out	NULL
.	NULL

Nuclear	NULL
extracts	NULL
,	NULL
prepared	NULL
from	NULL
unactivated	NULL
and	NULL
P/I-stimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
°°P	NULL
-labeled	NULL
probe	NULL
spanning	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
between	NULL
-460	NULL
and	NULL
-236	NULL
(	NULL
probe	NULL
A	NULL
)	NULL
.	NULL

A	NULL
time	NULL
course	NULL
analysis	NULL
revealed	NULL
the	NULL
presence	NULL
of	NULL
two	NULL
complexes	NULL
binding	NULL
to	NULL
this	NULL
region	NULL
.	NULL

An	NULL
upper	NULL
complex	NULL
,	NULL
designated	NULL
C2	NULL
,	NULL
was	NULL
constitutively	NULL
bound	NULL
in	NULL
unactivated	NULL
Jurkat	NULL
extracts	NULL
throughout	NULL
the	NULL
course	NULL
of	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
3	NULL
)	NULL
.	NULL

A	NULL
second	NULL
lower	NULL
complex	NULL
,	NULL
designated	NULL
C1	NULL
,	NULL
bound	NULL
only	NULL
upon	NULL
P/I	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
Lane	NULL
2	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
the	NULL
nature	NULL
of	NULL
the	NULL
C1	NULL
and	NULL
C2	NULL
com-plexes	NULL
,	NULL
cold-target	NULL
competition	NULL
was	NULL
carried	NULL
out	NULL
with	NULL
25-fold	NULL
excesses	NULL
of	NULL
the	NULL
Sp1	NULL
,	NULL
NF-kB	NULL
,	NULL
and	NULL
AP-1	NULL
consensus	NULL
elements	NULL
.	NULL

As	NULL
shown	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
CZ	NULL
binding	NULL
was	NULL
inhibited	NULL
by	NULL
Sp1-specific	NULL
oligonucleotides	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
Sp1-like	NULL
transcription	NULL
factor	NULL
at	NULL
this	NULL
site	NULL
.	NULL

C1	NULL
binding	NULL
was	NULL
specifically	NULL
competed	NULL
by	NULL
using	NULL
«	NULL
kB	NULL
consensus	NULL
oligonucleotides	NULL
derived	NULL
from	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
long	NULL
terminal	NULL
repeat	NULL
(	NULL
HIV	NULL
LTR	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

Other	NULL
cold-target	NULL
consensus	NULL
elements	NULL
tested	NULL
,	NULL
including	NULL
AP-1	NULL
,	NULL
AP-2	NULL
,	NULL
NF-ATp	NULL
,	NULL
and	NULL
GAS	NULL
,	NULL
were	NULL
incapable	NULL
of	NULL
inhibiting	NULL
either	NULL
C1	NULL
or	NULL
C2	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
,	NULL
lane	NULL
7	NULL
,	NULL
and	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
in	NULL
the	NULL
promoter	NULL
region	NULL
required	NULL
for	NULL
activation-dependent	NULL
Fas	NULL
upregulation	NULL
,	NULL
Spl	NULL
2102	NULL
CHAN	NULL
ET	NULL
AL	NULL
.	NULL

A5	NULL
A54	NULL
C	NULL
460	NULL
CTCGAGGTCC	NULL
TCACCTGAAG	NULL
TGAGCATGCC	NULL
AGCCACTGCA	NULL
NFB	NULL
__	NULL
___	NULL
aas	NULL
420	NULL
GGAACGECCC	NULL
aeaacagaaa	NULL
TacccaTtTo	NULL
:	NULL
Técaaceaac	NULL
Ass	NULL
NFATprAP-2	NULL
«	NULL
380	NULL
CCTGACTCCT	NULL
TCCTCACCCT	NULL
GAGTICTICCC	NULL
:	NULL
GCTCCCTACC	NULL
A	NULL
5.7	NULL
340	NULL
CGCGCGCAGG	NULL
CCAAGTTGCT	NULL
GAATCAATGG	NULL
AGCCCTCCCC	NULL
;	NULL
295/-286	NULL
300	NULL
AACCCG	NULL
@	NULL
@	NULL
C	NULL
@	NULL
TTCCCCAGCG	NULL
AGGCTTCCTT	NULL
CCCATCCTCC	NULL
A	NULL
5.8	NULL
NFxB	NULL
A6	NULL
250	NULL
TGACCACCGGIGGCTT	NULL
LtCaT	NULL
@	NULL
aGCTcaTCT	NULL
C	NULL
-230	NULL
NE-	NULL
«	NULL
B	NULL
NF-	NULL
«	NULL
B	NULL
--	NULL
B	NULL
A60	NULL
400	NULL
-300	NULL
-200	NULL
-100	NULL
19	NULL
460	NULL
A5	NULL
Lue	NULL
-429	NULL
A5.4	NULL
Luc	NULL
366	NULL
A5.5	NULL
-Lue	NULL
19	NULL
«	NULL
306	NULL
A5.7	NULL
Luc	NULL
259	NULL
A5.8	NULL
Lue	NULL
240	NULL
A6	NULL
-Lue	NULL
Relative	NULL
Fold	NULL
Induction	NULL
FIG	NULL
.	NULL

3	NULL
.	NULL

Localization	NULL
of	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
The	NULL
fas	NULL
nucleotide	NULL
sequence	NULL
between	NULL
-460	NULL
and	NULL
-230	NULL
is	NULL
shown	NULL
with	NULL
known	NULL
consensus	NULL
transcription	NULL
factor	NULL
elements	NULL
indicated	NULL
(	NULL
shaded	NULL
areas	NULL
)	NULL
.	NULL

The	NULL
location	NULL
and	NULL
designation	NULL
of	NULL
the	NULL
various	NULL
deletion	NULL
constructs	NULL
are	NULL
indicated	NULL
by	NULL
the	NULL
solid	NULL
arrow	NULL
.	NULL

(	NULL
B	NULL
)	NULL
P/I	NULL
inducibility	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
localizes	NULL
between	NULL
nucleotides	NULL
-306	NULL
and	NULL
-260	NULL
.	NULL

Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
10	NULL
g	NULL
of	NULL
the	NULL
various	NULL
deletion	NULL
constructs	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
pRL-tk	NULL
as	NULL
the	NULL
normalizing	NULL
vector	NULL
were	NULL
left	NULL
untreated	NULL
(	NULL
0	NULL
)	NULL
or	NULL
activated	NULL
with	NULL
P/I	NULL
(	NULL
@	NULL
I	NULL
)	NULL
for	NULL
8	NULL
h	NULL
before	NULL
extracts	NULL
were	NULL
prepared	NULL
for	NULL
luciferase	NULL
activity	NULL
measurements	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
averages	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
+	NULL
standard	NULL
deviation	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
relative	NULL
fold	NULL
induction	NULL
of	NULL
the	NULL
various	NULL
deletion	NULL
constructs	NULL
over	NULL
the	NULL
untreated	NULL
,	NULL
normalized	NULL
A5-Luc	NULL
luciferase	NULL
value	NULL
.	NULL

bound	NULL
constitutively	NULL
,	NULL
while	NULL
NF-	NULL
«	NULL
B	NULL
complex	NULL
formation	NULL
occurred	NULL
only	NULL
in	NULL
response	NULL
to	NULL
stimulation	NULL
.	NULL

Activation-dependent	NULL
Fas	NULL
promoter	NULL
induction	NULL
requires	NULL
nucleotides	NULL
-306	NULL
to	NULL
-260	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
region	NULL
between	NULL
-460	NULL
and	NULL
-240	NULL
in	NULL
further	NULL
detail	NULL
,	NULL
sequential	NULL
deletions	NULL
of	NULL
A5-Luc	NULL
spanning	NULL
40-	NULL
to	NULL
60-bp	NULL
intervals	NULL
were	NULL
generated	NULL
by	NULL
PCR	NULL
.	NULL

The	NULL
precise	NULL
sequences	NULL
contained	NULL
in	NULL
the	NULL
various	NULL
constructs	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3A	NULL
.	NULL

Basal	NULL
and	NULL
inducible	NULL
promoter	NULL
activities	NULL
in	NULL
transiently	NULL
transfected	NULL
,	NULL
unactivated	NULL
,	NULL
and	NULL
P/I-stimulated	NULL
Jurkat	NULL
cells	NULL
,	NULL
respectively	NULL
,	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3B	NULL
.	NULL

Deletion	NULL
of	NULL
nucleotides	NULL
-460	NULL
to	NULL
-306	NULL
and	NULL
-259	NULL
to	NULL
-240	NULL
had	NULL
little	NULL
effect	NULL
on	NULL
the	NULL
activation-dependent	NULL
induction	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
(	NULL
AS	NULL
to	NULL
A5.7	NULL
,	NULL
A5.8	NULL
to	NULL
A6	NULL
)	NULL
,	NULL
ruling	NULL
out	NULL
the	NULL
contribution	NULL
of	NULL
the	NULL
consensus	NULL
NF-	NULL
«	NULL
B	NULL
sites	NULL
located	NULL
at	NULL
-421	NULL
to	NULL
-412	NULL
and	NULL
-252	NULL
to	NULL
-243	NULL
,	NULL
the	NULL
GAS	NULL
element	NULL
at	NULL
-394	NULL
to	NULL
-386	NULL
,	NULL
and	NULL
the	NULL
NF-ATp-AP-2	NULL
site	NULL
at	NULL
positions	NULL
-358	NULL
to	NULL
-345	NULL
.	NULL

When	NULL
nucleotides	NULL
-306	NULL
to	NULL
-260	NULL
(	NULL
A5.7	NULL
to	NULL
A5.8	NULL
)	NULL
were	NULL
deleted	NULL
,	NULL
however	NULL
,	NULL
inducible	NULL
reporter	NULL
activity	NULL
was	NULL
reduced	NULL
to	NULL
that	NULL
observed	NULL
with	NULL
the	NULL
A6	NULL
construct	NULL
.	NULL

The	NULL
sequences	NULL
between	NULL
-306	NULL
and	NULL
-260	NULL
were	NULL
devoid	NULL
of	NULL
any	NULL
mapped	NULL
transcription	NULL
factor	NULL
consensus	NULL
sites	NULL
,	NULL
except	NULL
for	NULL
a	NULL
kB-like	NULL
motif	NULL
present	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
.	NULL

This	NULL
motif	NULL
con	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

tains	NULL
the	NULL
sequence	NULL
GGGCGTTCCC	NULL
and	NULL
differs	NULL
from	NULL
the	NULL
derived	NULL
consensus	NULL
kB	NULL
p50-p65	NULL
heterodimer	NULL
motif	NULL
GGGRNNY	NULL
YCC	NULL
(	NULL
20	NULL
,	NULL
30	NULL
,	NULL
48	NULL
)	NULL
at	NULL
position	NULL
4	NULL
(	NULL
change	NULL
of	NULL
R	NULL
to	NULL
C	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
however	NULL
,	NULL
the	NULL
critical	NULL
G	NULL
,	NULL
_	NULL
,	NULL
nucleotides	NULL
necessary	NULL
for	NULL
p50	NULL
binding	NULL
are	NULL
maintained	NULL
.	NULL

Comparison	NULL
of	NULL
this	NULL
motif	NULL
to	NULL
a	NULL
consensus	NULL
Sp1	NULL
site	NULL
,	NULL
KRGGCGKRRY	NULL
(	NULL
35	NULL
)	NULL
,	NULL
also	NULL
revealed	NULL
homology	NULL
at	NULL
8	NULL
of	NULL
10	NULL
residues	NULL
,	NULL
indicating	NULL
a	NULL
possible	NULL
interaction	NULL
with	NULL
this	NULL
transcription	NULL
factor	NULL
.	NULL

Taken	NULL
together	NULL
with	NULL
results	NULL
from	NULL
our	NULL
previous	NULL
studies	NULL
showing	NULL
that	NULL
complexes	NULL
that	NULL
could	NULL
be	NULL
competed	NULL
with	NULL
Sp1	NULL
and	NULL
NF-kB	NULL
oligonucleotides	NULL
bound	NULL
to	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
at	NULL
-406	NULL
to	NULL
-236	NULL
,	NULL
it	NULL
seemed	NULL
likely	NULL
that	NULL
these	NULL
transcription	NULL
factors	NULL
,	NULL
acting	NULL
alone	NULL
or	NULL
in	NULL
combination	NULL
,	NULL
might	NULL
be	NULL
required	NULL
for	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

Spl	NULL
and	NULL
NF-	NULL
<	NULL
B	NULL
conjointly	NULL
bind	NULL
at	NULL
the	NULL
motif	NULL
(	NULL
-295	NULL
to	NULL
-286	NULL
)	NULL
during	NULL
activation-driven	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

To	NULL
further	NULL
investigate	NULL
the	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
fas	NULL
promoter	NULL
upregulation	NULL
in	NULL
P/T-activated	NULL
Jurkat	NULL
cells	NULL
,	NULL
EMSA	NULL
analyses	NULL
of	NULL
nuclear	NULL
extracts	NULL
were	NULL
performed	NULL
with	NULL
a	NULL
29-bp	NULL
probe	NULL
spanning	NULL
the	NULL
noncanonical	NULL
«	NULL
B-Sp1-like	NULL
motif	NULL
(	NULL
-306	NULL
to	NULL
-278	NULL
;	NULL
probe	NULL
B	NULL
)	NULL
.	NULL

In	NULL
concert	NULL
with	NULL
our	NULL
previous	NULL
observations	NULL
with	NULL
probe	NULL
A	NULL
,	NULL
spanning	NULL
nucleotides	NULL
-460	NULL
to	NULL
-236	NULL
(	NULL
Fig	NULL
.	NULL

2C	NULL
)	NULL
,	NULL
we	NULL
observed	NULL
constitutive	NULL
binding	NULL
of	NULL
the	NULL
CZ	NULL
complex	NULL
in	NULL
both	NULL
unactivated	NULL
and	NULL
P/I-stimulated	NULL
extracts	NULL
and	NULL
inducible	NULL
binding	NULL
of	NULL
the	NULL
C1	NULL
complex	NULL
upon	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

C1	NULL
was	NULL
induced	NULL
de	NULL
novo	NULL
within	NULL
15	NULL
min	NULL
of	NULL
P/I	NULL
addition	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
persisted	NULL
for	NULL
up	NULL
to	NULL
2	NULL
h	NULL
postactivation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

The	NULL
specificities	NULL
of	NULL
C1	NULL
and	NULL
C2	NULL
binding	NULL
to	NULL
probe	NULL
B	NULL
were	NULL
first	NULL
demonstrated	NULL
by	NULL
cold-com-petition	NULL
assays	NULL
using	NULL
excess	NULL
unlabeled	NULL
probe	NULL
B	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

Jurkat	NULL
extracts	NULL
were	NULL
coincubated	NULL
with	NULL
radiolabeled	NULL
probe	NULL
B	NULL
and	NULL
25-fold	NULL
excesses	NULL
of	NULL
either	NULL
unlabeled	NULL
AP-1-	NULL
or	NULL
NF-AT-specific	NULL
oligonucleotides	NULL
or	NULL
a	NULL
mutated	NULL
probe	NULL
B	NULL
(	NULL
GGG	NULL
to	NULL
TTT	NULL
[	NULL
see	NULL
below	NULL
]	NULL
)	NULL
.	NULL

Under	NULL
these	NULL
conditions	NULL
,	NULL
no	NULL
displacement	NULL
was	NULL
observed	NULL
in	NULL
either	NULL
C1	NULL
or	NULL
C2	NULL
binding	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
7	NULL
,	NULL
8	NULL
,	NULL
and	NULL
10	NULL
)	NULL
.	NULL

To	NULL
investigate	NULL
Sp1-NF-	NULL
«	NULL
B	NULL
binding	NULL
to	NULL
probe	NULL
B	NULL
,	NULL
Jurkat	NULL
extracts	NULL
were	NULL
incubated	NULL
with	NULL
labeled	NULL
probe	NULL
B	NULL
and	NULL
increasing	NULL
concentrations	NULL
of	NULL
unlabeled	NULL
NF-kB	NULL
consensus	NULL
oligo-nucleotides	NULL
.	NULL

With	NULL
a	NULL
25-fold	NULL
excess	NULL
,	NULL
NF-kB	NULL
oligonucleotides	NULL
effectively	NULL
competed	NULL
the	NULL
inducible	NULL
C1	NULL
complex	NULL
,	NULL
but	NULL
not	NULL
the	NULL
C2	NULL
complex	NULL
.	NULL

However	NULL
,	NULL
at	NULL
100-fold	NULL
excess	NULL
,	NULL
both	NULL
C2	NULL
and	NULL
nonspecific	NULL
binding	NULL
were	NULL
inhibited	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
11	NULL
to	NULL
12	NULL
)	NULL
.	NULL

Increasing	NULL
concentrations	NULL
of	NULL
Spl	NULL
oligonucleotides	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
specifically	NULL
competed	NULL
the	NULL
constitutive	NULL
C2	NULL
complex	NULL
,	NULL
but	NULL
not	NULL
the	NULL
inducible	NULL
C1	NULL
binding	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
,	NULL
lanes	NULL
13	NULL
and	NULL
14	NULL
)	NULL
.	NULL

We	NULL
next	NULL
addressed	NULL
whether	NULL
extracts	NULL
from	NULL
P/I-activated	NULL
Jurkat	NULL
cells	NULL
bound	NULL
to	NULL
probe	NULL
B	NULL
could	NULL
be	NULL
supershifted	NULL
by	NULL
using	NULL
antibodies	NULL
against	NULL
various	NULL
NF-	NULL
«	NULL
kB-Rel	NULL
family	NULL
members	NULL
,	NULL
including	NULL
p50	NULL
,	NULL
p52	NULL
,	NULL
p65	NULL
,	NULL
c-Rel	NULL
,	NULL
and	NULL
RelB	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
the	NULL
inducible	NULL
C1	NULL
complex	NULL
was	NULL
supershifted	NULL
with	NULL
antibodies	NULL
against	NULL
p50	NULL
,	NULL
p65	NULL
,	NULL
and	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
,	NULL
c-Rel	NULL
,	NULL
indicating	NULL
the	NULL
presence	NULL
of	NULL
these	NULL
heterodimers	NULL
in	NULL
the	NULL
shifted	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
2	NULL
to	NULL
4	NULL
)	NULL
.	NULL

No	NULL
such	NULL
shifted	NULL
complexes	NULL
were	NULL
observed	NULL
in	NULL
extracts	NULL
from	NULL
unactivated	NULL
Jurkat	NULL
cells	NULL
lacking	NULL
the	NULL
inducible	NULL
C1	NULL
complex	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Antibodies	NULL
against	NULL
Sp1	NULL
,	NULL
on	NULL
the	NULL
other	NULL
hand	NULL
,	NULL
shifted	NULL
the	NULL
constitutive	NULL
C2	NULL
complex	NULL
in	NULL
both	NULL
activated	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
,	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
and	NULL
unactivated	NULL
Jurkat	NULL
extracts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
imply	NULL
that	NULL
Spl	NULL
is	NULL
bound	NULL
to	NULL
the	NULL
kB-Sp1l	NULL
site	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
during	NULL
normal	NULL
basal	NULL
transcription	NULL
,	NULL
whereas	NULL
NF-kB	NULL
p50-p65	NULL
heterodimers	NULL
occupy	NULL
the	NULL
<	NULL
B-Sp1	NULL
site	NULL
during	NULL
activation-driven	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

Mutually	NULL
exclusive	NULL
binding	NULL
of	NULL
Spl	NULL
versus	NULL
NF-KB	NULL
at	NULL
nucleotides	NULL
-295	NULL
to	NULL
-286	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
binding	NULL
of	NULL
Spl	NULL
and	NULL
NF-kB	NULL
to	NULL
the	NULL
-295	NULL
to	NULL
-286	NULL
site	NULL
in	NULL
the	NULL
fas	NULL
promoter	NULL
occurs	NULL
concurrently	NULL
or	NULL
as	NULL
a	NULL
mutually	NULL
exclusive	NULL
event	NULL
,	NULL
EMSA	NULL
analyses	NULL
were	NULL
performed	NULL
with	NULL
probe	NULL
B	NULL
with	NULL
recombinant	NULL
Sp1	NULL
and	NULL
increasing	NULL
amounts	NULL
of	NULL
recombinant	NULL
p50	NULL
.	NULL

Consistent	NULL
with	NULL
our	NULL
observations	NULL
using	NULL
extracts	NULL
from	NULL
unactivated	NULL
Jurkat	NULL
cells	NULL
,	NULL
a	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
[	NULL
4	NULL
]	NULL
Time	NULL
(	NULL
min	NULL
.	NULL
)	NULL

Competition	NULL
&	NULL
«	NULL
&	NULL
A	NULL
,	NULL
F	NULL
.	NULL

$	NULL
$	NULL
``	NULL
&	NULL
``	NULL
%	NULL
A	NULL
.	NULL

®	NULL
CCC	NULL
{	NULL
&	NULL
a	NULL
¢	NULL
»	NULL
@	NULL
_®P	NULL
A	NULL
J	NULL
24	NULL
Free	NULL
Probe	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
11	NULL
12	NULL
13	NULL
14	NULL
Probe	NULL
B	NULL
:	NULL
-306	NULL
/	NULL
-278	NULL
\\	NULL
®	NULL
o	NULL
©	NULL
A	NULL
,	NULL
o	NULL
C3	NULL
&	NULL
&	NULL
&	NULL
``	NULL
&	NULL
0000	NULL
C	NULL
Antibody	NULL
:	NULL
C	NULL
P	NULL
L4	NULL
C	NULL
$	NULL
@	NULL
#	NULL
6	NULL
-G-	NULL
p65/c-rel	NULL
-	NULL
<	NULL
4-	NULL
Spi	NULL
--	NULL
p50	NULL
Probe	NULL
B	NULL
:	NULL
-306	NULL
/	NULL
-278	NULL
Sp1	NULL
(	NULL
120ng	NULL
)	NULL
+	NULL
-o	NULL
+	NULL
+	NULL
+/+	NULL
0	NULL
0	NULL
5	NULL
10	NULL
20	NULL
40	NULL
p50	NULL
(	NULL
ng	NULL
)	NULL
:	NULL
|	NULL
Sp1	NULL
:	NULL
:	NULL
|	NULL
pso	NULL
Free	NULL
Probe	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
Probe	NULL
B	NULL
:	NULL
-306/-278	NULL
FIG	NULL
.	NULL

4	NULL
.	NULL

In	NULL
vitro	NULL
analysis	NULL
of	NULL
a	NULL
potential	NULL
«	NULL
B-Sp1	NULL
site	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Time	NULL
course	NULL
analysis	NULL
of	NULL
complex	NULL
binding	NULL
to	NULL
probe	NULL
B	NULL
(	NULL
-306	NULL
to	NULL
-278	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
P/I	NULL
for	NULL
the	NULL
indicated	NULL
time	NULL
,	NULL
nuclear	NULL
extracts	NULL
were	NULL
harvested	NULL
,	NULL
and	NULL
EMSA	NULL
analysis	NULL
was	NULL
performed	NULL
with	NULL
*°P-labeled	NULL
probe	NULL
B	NULL
(	NULL
left	NULL
panel	NULL
,	NULL
lanes	NULL
1	NULL
to	NULL
5	NULL
)	NULL
.	NULL

TRANSCRIPTIONAL	NULL
REGULATION	NULL
OF	NULL
THE	NULL
HUMAN	NULL
f	NULL
@	NULL
s	NULL
PROMOTER	NULL
-	NULL
2103	NULL
single	NULL
complex	NULL
is	NULL
observed	NULL
when	NULL
probe	NULL
B	NULL
is	NULL
mixed	NULL
with	NULL
Spl	NULL
alone	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
.	NULL

As	NULL
increasing	NULL
amounts	NULL
of	NULL
recombinant	NULL
p50	NULL
are	NULL
added	NULL
,	NULL
however	NULL
,	NULL
the	NULL
intensity	NULL
of	NULL
the	NULL
Sp1	NULL
complex	NULL
is	NULL
decreased	NULL
,	NULL
with	NULL
a	NULL
concomitant	NULL
increase	NULL
in	NULL
the	NULL
lower	NULL
p50	NULL
binding	NULL
complex	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
,	NULL
lanes	NULL
3	NULL
to	NULL
6	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
contains	NULL
a	NULL
single	NULL
<	NULL
B-Sp1	NULL
binding	NULL
motif	NULL
to	NULL
which	NULL
either	NULL
Spl	NULL
or	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
exclusively	NULL
bound	NULL
.	NULL

Upon	NULL
cellular	NULL
activation	NULL
,	NULL
constitutively	NULL
bound	NULL
Sp1	NULL
is	NULL
likely	NULL
displaced	NULL
by	NULL
NF-xB	NULL
to	NULL
drive	NULL
fas	NULL
promoter	NULL
upregulation	NULL
.	NULL

NF-B	NULL
recruitment	NULL
regulates	NULL
activation-dependent	NULL
Fas	NULL
promoter	NULL
induction	NULL
.	NULL

Although	NULL
the	NULL
above	NULL
in	NULL
vitro	NULL
analyses	NULL
document	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
heterodimers	NULL
are	NULL
rapidly	NULL
recruited	NULL
to	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
controlling	NULL
activation-dependent	NULL
induction	NULL
,	NULL
these	NULL
studies	NULL
do	NULL
not	NULL
address	NULL
the	NULL
functional	NULL
consequences	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
NF-kB	NULL
recruitment	NULL
on	NULL
fas	NULL
promoter	NULL
activity	NULL
.	NULL

To	NULL
investigate	NULL
the	NULL
role	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
recruitment	NULL
in	NULL
activation-driven	NULL
fas	NULL
upregulation	NULL
,	NULL
the	NULL
effects	NULL
of	NULL
various	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
function	NULL
were	NULL
examined	NULL
.	NULL

Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
A5-Luc	NULL
reporter	NULL
were	NULL
pretreated	NULL
with	NULL
two	NULL
pharmacological	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
then	NULL
activated	NULL
with	NULL
P/I	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5A	NULL
,	NULL
cyclosporin	NULL
A	NULL
pretreatment	NULL
of	NULL
Jurkat	NULL
cells	NULL
completely	NULL
prevented	NULL
P/I-dependent	NULL
upregulation	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
.	NULL

Because	NULL
this	NULL
calcineurin	NULL
inhibitor	NULL
can	NULL
inhibit	NULL
NF-AT	NULL
translocation	NULL
and	NULL
disrupt	NULL
Ca**	NULL
signals	NULL
leading	NULL
to	NULL
NF-kB	NULL
induction	NULL
(	NULL
36	NULL
)	NULL
,	NULL
the	NULL
fungal	NULL
metabolite	NULL
gliotoxin	NULL
,	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
IxB-	NULL
«	NULL
degradation	NULL
and	NULL
NF-kB	NULL
translocation	NULL
,	NULL
was	NULL
also	NULL
used	NULL
(	NULL
46	NULL
)	NULL
.	NULL

Gliotoxin	NULL
,	NULL
but	NULL
not	NULL
the	NULL
inactive	NULL
gliotoxin	NULL
derivative	NULL
bis-dethio-bis	NULL
(	NULL
methylthi0	NULL
)	NULL
gliotoxin	NULL
,	NULL
completely	NULL
abolished	NULL
P/I	NULL
inducibility	NULL
of	NULL
the	NULL
AS-Luc	NULL
reporter	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
notion	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
recruitment	NULL
was	NULL
functionally	NULL
required	NULL
for	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

The	NULL
critical	NULL
requirement	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
recruitment	NULL
was	NULL
additionally	NULL
verified	NULL
in	NULL
Jurkat	NULL
cells	NULL
overexpressing	NULL
wild-type	NULL
IxB-	NULL
«	NULL
.	NULL

The	NULL
overexpression	NULL
of	NULL
IxB-	NULL
«	NULL
,	NULL
a	NULL
natural	NULL
inhibitor	NULL
of	NULL
NF-kB	NULL
translocation	NULL
,	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
effectively	NULL
block	NULL
«	NULL
B-dependent	NULL
transactivation	NULL
(	NULL
31	NULL
,	NULL
32	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

5B	NULL
,	NULL
P/T-activated	NULL
Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
AS-Lue	NULL
reporter	NULL
and	NULL
RsV-IxB-	NULL
«	NULL
expression	NULL
plasmid	NULL
showed	NULL
a	NULL
dose-dependent	NULL
decrease	NULL
in	NULL
fas	NULL
promoter	NULL
activity	NULL
with	NULL
increasing	NULL
IxB-a	NULL
«	NULL
concentration	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
strongly	NULL
support	NULL
the	NULL
premise	NULL
that	NULL
NF-kB	NULL
translocation	NULL
is	NULL
essential	NULL
for	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

The	NULL
B-like	NULL
motif	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
controls	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
responses	NULL
.	NULL

While	NULL
previous	NULL
experiments	NULL
indicated	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
was	NULL
essential	NULL
for	NULL
fas	NULL
promoter	NULL
induction	NULL
,	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
kB	NULL
element	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
remained	NULL
to	NULL
be	NULL
tested	NULL
.	NULL

To	NULL
Cold	NULL
competition	NULL
was	NULL
performed	NULL
with	NULL
1-h-activated	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
with	NULL
a	NULL
25-fold	NULL
excess	NULL
of	NULL
consensus	NULL
oligonucleotides	NULL
for	NULL
the	NULL
transcription	NULL
factors	NULL
AP-1	NULL
,	NULL
NF-AT	NULL
,	NULL
wild-type	NULL
probe	NULL
B	NULL
(	NULL
W-T	NULL
)	NULL
,	NULL
or	NULL
mutated	NULL
probe	NULL
B	NULL
(	NULL
Mut	NULL
.	NULL
)	NULL

added	NULL
prior	NULL
to	NULL
incubation	NULL
with	NULL
*°P-labeled	NULL
probe	NULL
B	NULL
(	NULL
lanes	NULL
7	NULL
to	NULL
10	NULL
)	NULL
.	NULL

For	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
competition	NULL
,	NULL
a	NULL
25-fold	NULL
excess	NULL
(	NULL
lanes	NULL
11	NULL
and	NULL
13	NULL
)	NULL
and	NULL
100-fold	NULL
excess	NULL
(	NULL
lanes	NULL
12	NULL
and	NULL
14	NULL
)	NULL
of	NULL
consensus	NULL
oligonucleotides	NULL
were	NULL
added	NULL
to	NULL
equivalent	NULL
amounts	NULL
of	NULL
P/I-activated	NULL
nuclear	NULL
extracts	NULL
prior	NULL
to	NULL
addition	NULL
of	NULL
*°P-labeled	NULL
probe	NULL
B	NULL
.	NULL

N.S	NULL
.	NULL

,	NULL
nonspecific	NULL
binding	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Supershift	NULL
analyses	NULL
of	NULL
P/l-activated	NULL
Jurkat	NULL
cell	NULL
nuclear	NULL
extracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
subjected	NULL
to	NULL
EMSA	NULL
analysis	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
specific	NULL
antisera	NULL
(	NULL
lanes	NULL
2	NULL
to	NULL
8	NULL
)	NULL
,	NULL
or	NULL
preimmune	NULL
IgG	NULL
(	NULL
lane	NULL
9	NULL
)	NULL
.	NULL

With	NULL
two	NULL
different	NULL
anti-Sp1	NULL
antisera	NULL
,	NULL
probe	NULL
B	NULL
binding	NULL
to	NULL
the	NULL
upper	NULL
C2	NULL
complex	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
either	NULL
shifted	NULL
or	NULL
inhibited	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
)	NULL
.	NULL

Arrows	NULL
indicate	NULL
the	NULL
identity	NULL
of	NULL
the	NULL
shifted	NULL
complexes	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Mutual	NULL
exclusive	NULL
binding	NULL
of	NULL
Sp1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
to	NULL
probe	NULL
B.	NULL
Recombinant	NULL
Sp1	NULL
(	NULL
4	NULL
fpu	NULL
[	NULL
120	NULL
ng	NULL
]	NULL
)	NULL
was	NULL
preincubated	NULL
with	NULL
12,500	NULL
cpm	NULL
of	NULL
radiolabeled	NULL
probe	NULL
B	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
increasing	NULL
amounts	NULL
(	NULL
0	NULL
to	NULL
40	NULL
ng	NULL
)	NULL
of	NULL
recombinant	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
(	NULL
lanes	NULL
3	NULL
to	NULL
6	NULL
)	NULL
prior	NULL
to	NULL
EMSA	NULL
analysis	NULL
.	NULL

Brackets	NULL
indicate	NULL
the	NULL
Sp1-probe	NULL
B	NULL
and	NULL
p30-probe	NULL
B	NULL
complexes	NULL
.	NULL

2104	NULL
CHAN	NULL
ET	NULL
AL	NULL
.	NULL

[	NULL
-	NULL
]	NULL
.	NULL

None	NULL
©	NULL
P/	NULL
15	NULL
10	NULL
Relative	NULL
Fold	NULL
Induction	NULL
None	NULL
-	NULL
CsA	NULL
GT	NULL
DGT	NULL
Inhibitors	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

100	NULL
5	NULL
T	NULL
5	NULL
75	NULL
T.	NULL
€	NULL
&	NULL
-	NULL
50	NULL
T	NULL
C	NULL
<	NULL
I	NULL
o	NULL
[	NULL
vet	NULL
25	NULL
32	NULL
T	NULL
0	NULL
0	NULL
2.5	NULL
5	NULL
7.5	NULL
10	NULL
RsV-IxBa	NULL
co-transfected	NULL
(	NULL
ug	NULL
)	NULL
FIG	NULL
.	NULL

5	NULL
.	NULL

Inhibition	NULL
of	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
upregulation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Pharmacological	NULL
inhibition	NULL
of	NULL
A5-Luc	NULL
induction	NULL
by	NULL
P/I	NULL
.	NULL

Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
10	NULL
pg	NULL
of	NULL
A5-Lue	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
pRL-tk	NULL
were	NULL
preincubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
None	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
[	NULL
1	NULL
pg/ml	NULL
)	NULL
)	NULL
,	NULL
gliotoxin	NULL
(	NULL
GT	NULL
[	NULL
1	NULL
pg/ml	NULL
]	NULL
)	NULL
,	NULL
or	NULL
bis-dethio-bis	NULL
(	NULL
methylthio	NULL
)	NULL
gliotoxin	NULL
(	NULL
DGT	NULL
[	NULL
3	NULL
pg/ml	NULL
]	NULL
)	NULL
for	NULL
30	NULL
min	NULL
prior	NULL
to	NULL
P/I	NULL
stimulation	NULL
for	NULL
8	NULL
h.	NULL
Following	NULL
incubation	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
for	NULL
extract	NULL
preparation	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
determined	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
independent	NULL
experiments	NULL
+	NULL
standard	NULL
deviation	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
relative	NULL
fold	NULL
induction	NULL
over	NULL
normalized	NULL
untreated	NULL
A5-Luc	NULL
activity	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Dose-dependent	NULL
inhibition	NULL
of	NULL
P/I-inducible	NULL
A5-Luc	NULL
reporter	NULL
activity	NULL
by	NULL
I	NULL
«	NULL
Ba	NULL
.	NULL

Increasing	NULL
amounts	NULL
of	NULL
wild-type	NULL
RsV-IxBa	NULL
(	NULL
ID	NULL
)	NULL
or	NULL
vector	NULL
control	NULL
(	NULL
®	NULL
)	NULL
expression	NULL
plasmid	NULL
were	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
A5-Lue	NULL
and	NULL
10	NULL
ng	NULL
of	NULL
pRL-tk	NULL
40	NULL
h	NULL
prior	NULL
to	NULL
P/I	NULL
activation	NULL
.	NULL

Cells	NULL
were	NULL
harvested	NULL
for	NULL
extract	NULL
preparation	NULL
after	NULL
8	NULL
h	NULL
of	NULL
P/I	NULL
exposure	NULL
,	NULL
and	NULL
luciferase	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
averages	NULL
from	NULL
two	NULL
independent	NULL
experiments	NULL
+	NULL
standard	NULL
deviation	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
percent	NULL
inhibition	NULL
of	NULL
P/I-induced	NULL
,	NULL
normalized	NULL
A5-Luc	NULL
reporter	NULL
activity	NULL
.	NULL

determine	NULL
the	NULL
specific	NULL
contribution	NULL
of	NULL
this	NULL
kB-Sp1l	NULL
element	NULL
,	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
the	NULL
composite	NULL
site	NULL
altered	NULL
(	NULL
as	NULL
underlined	NULL
)	NULL
(	NULL
GGGCGTTCCC	NULL
to	NULL
TTTCGTTCCC	NULL
)	NULL
and	NULL
with	NULL
a	NULL
mutagenized	NULL
A5	NULL
fas	NULL
reporter	NULL
construct	NULL
generated	NULL
by	NULL
PCR	NULL
.	NULL

This	NULL
construct	NULL
was	NULL
designated	NULL
ASM5.7-Luc	NULL
.	NULL

As	NULL
a	NULL
control	NULL
,	NULL
a	NULL
second	NULL
A5	NULL
reporter	NULL
construct	NULL
containing	NULL
the	NULL
xB	NULL
site	NULL
at	NULL
-262	NULL
to	NULL
-253	NULL
was	NULL
also	NULL
mutagenized	NULL
(	NULL
ASMS5.8	NULL
;	NULL
GGGGCTTITTC	NULL
to	NULL
GCCYCTTTITC	NULL
)	NULL
and	NULL
used	NULL
in	NULL
reporter	NULL
assays	NULL
.	NULL

Jurkat	NULL
cells	NULL
transiently	NULL
transfected	NULL
with	NULL
the	NULL
wild-type	NULL
AS-Lue	NULL
construct	NULL
,	NULL
ASMS5.7-Luc	NULL
,	NULL
or	NULL
the	NULL
ASMS5.8-Luc	NULL
control	NULL
were	NULL
activated	NULL
with	NULL
P/I	NULL
,	NULL
and	NULL
reporter	NULL
activity	NULL
was	NULL
measured	NULL
.	NULL

Similar	NULL
to	NULL
previous	NULL
experiments	NULL
with	NULL
the	NULL
A5	NULL
deletion	NULL
constructs	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
both	NULL
wild-type	NULL
AS-Lue	NULL
and	NULL
ASM5.8-Luc	NULL
showed	NULL
an	NULL
approximate	NULL
15-fold	NULL
induction	NULL
following	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
ASM5.7-Luc	NULL
reporter	NULL
activity	NULL
increased	NULL
only	NULL
threefold	NULL
after	NULL
P/I	NULL
treatment	NULL
.	NULL

These	NULL
results	NULL
document	NULL
the	NULL
functional	NULL
contribution	NULL
of	NULL
the	NULL
kB-Spl	NULL
site	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
,	NULL
but	NULL
not	NULL
the	NULL
consensus	NULL
NF-kB	NULL
site	NULL
at	NULL
-262	NULL
to	NULL
-243	NULL
,	NULL
in	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

Interestingly	NULL
,	NULL
while	NULL
ASM5.7-Lue	NULL
induction	NULL
was	NULL
significantly	NULL
suppressed	NULL
compared	NULL
to	NULL
that	NULL
of	NULL
the	NULL
wild-type	NULL
A5-Luc	NULL
construct	NULL
(	NULL
79.6	NULL
%	NULL
+	NULL
10.61	NULL
%	NULL
,	NULL
respectively	NULL
)	NULL
P/I	NULL
inducibility	NULL
was	NULL
not	NULL
entirely	NULL
abolished	NULL
.	NULL

Such	NULL
findings	NULL
suggest	NULL
that	NULL
an	NULL
additional	NULL
site	NULL
or	NULL
sites	NULL
,	NULL
perhaps	NULL
in	NULL
the	NULL
region	NULL
from	NULL
-19	NULL
to	NULL
-240	NULL
(	NULL
compare	NULL
Fig	NULL
.	NULL

3B	NULL
to	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
,	NULL
may	NULL
be	NULL
required	NULL
for	NULL
maximal	NULL
fas	NULL
promoter	NULL
induction	NULL
during	NULL
T-cell	NULL
activation	NULL
.	NULL

To	NULL
further	NULL
verify	NULL
the	NULL
transcriptional	NULL
contribution	NULL
of	NULL
the	NULL
-295	NULL
to	NULL
-286	NULL
kB-Sp1	NULL
composite	NULL
site	NULL
,	NULL
concatemer	NULL
constructs	NULL
containing	NULL
multiple	NULL
copies	NULL
of	NULL
this	NULL
element	NULL
upstream	NULL
of	NULL
a	NULL
thymidine	NULL
kinase	NULL
promoter-driven	NULL
luciferase	NULL
reporter	NULL
were	NULL
generated	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Constructs	NULL
containing	NULL
none	NULL
,	NULL
two	NULL
,	NULL
four	NULL
,	NULL
or	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
xB-Sp1	NULL
element	NULL
were	NULL
transiently	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
,	NULL
and	NULL
the	NULL
reporter	NULL
activity	NULL
was	NULL
measured	NULL
after	NULL
P/I	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
the	NULL
inducibility	NULL
of	NULL
the	NULL
con-catemer-reporter	NULL
constructs	NULL
increased	NULL
with	NULL
the	NULL
number	NULL
of	NULL
the	NULL
<	NULL
B-Sp1	NULL
elements	NULL
multimerized	NULL
,	NULL
with	NULL
six	NULL
copies	NULL
showing	NULL
a	NULL
>	NULL
35-fold	NULL
specific	NULL
induction	NULL
over	NULL
that	NULL
of	NULL
the	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
alone	NULL
.	NULL

As	NULL
observed	NULL
previously	NULL
with	NULL
the	NULL
A5-Luc	NULL
construct	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
,	NULL
P/I	NULL
inducibility	NULL
of	NULL
the	NULL
xB-Sp1	NULL
concatemers	NULL
was	NULL
specifically	NULL
eliminated	NULL
by	NULL
inhibitors	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
translocation	NULL
.	NULL

Fig	NULL
ures	NULL
6B	NULL
and	NULL
C	NULL
show	NULL
the	NULL
effects	NULL
of	NULL
gliotoxin	NULL
and	NULL
IxB-	NULL
«	NULL
overexpression	NULL
on	NULL
P/I	NULL
inducibility	NULL
of	NULL
the	NULL
<	NULL
B-Spl-containing	NULL
constructs	NULL
.	NULL

Furthermore	NULL
,	NULL
in	NULL
cells	NULL
transfected	NULL
with	NULL
six	NULL
copies	NULL
of	NULL
the	NULL
element	NULL
basal	NULL
reporter	NULL
activity	NULL
was	NULL
fourfold	NULL
higher	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
than	NULL
that	NULL
of	NULL
the	NULL
tk-Luc	NULL
reporter	NULL
alone	NULL
,	NULL
suggesting	NULL
a	NULL
possible	NULL
enhancement	NULL
of	NULL
constitutive	NULL
fas	NULL
promoter	NULL
regulation	NULL
by	NULL
multiple	NULL
Spl	NULL
sites	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
experiments	NULL
confirm	NULL
the	NULL
functional	NULL
significance	NULL
of	NULL
the	NULL
xB-Sp1	NULL
site	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
in	NULL
the	NULL
control	NULL
of	NULL
activation-driven	NULL
fas	NULL
promoter	NULL
induction	NULL
.	NULL

DISCUSSION	NULL
In	NULL
recent	NULL
years	NULL
,	NULL
much	NULL
attention	NULL
has	NULL
been	NULL
focused	NULL
on	NULL
how	NULL
the	NULL
immune	NULL
response	NULL
is	NULL
downregulated	NULL
.	NULL

Because	NULL
self-reactive	NULL
T	NULL
cells	NULL
are	NULL
ineffectively	NULL
deleted	NULL
by	NULL
negative	NULL
selection	NULL
in	NULL
the	NULL
thy-mus	NULL
,	NULL
the	NULL
preservation	NULL
of	NULL
immune	NULL
homeostasis	NULL
requires	NULL
self-regulatory	NULL
mechanisms	NULL
for	NULL
the	NULL
maintenance	NULL
of	NULL
tolerance	NULL
and	NULL
the	NULL
control	NULL
of	NULL
excessive	NULL
T-cell	NULL
proliferation	NULL
to	NULL
foreign	NULL
antigens	NULL
in	NULL
the	NULL
periphery	NULL
.	NULL

Apoptosis	NULL
is	NULL
responsible	NULL
for	NULL
maintaining	NULL
T-cell	NULL
homeostasis	NULL
by	NULL
at	NULL
least	NULL
two	NULL
mechanisms-AICD	NULL
that	NULL
occurs	NULL
after	NULL
TCR	NULL
ligation	NULL
by	NULL
antigen	NULL
and	NULL
passive	NULL
cell	NULL
death	NULL
that	NULL
occurs	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
antigen	NULL
or	NULL
cytokine	NULL
stimulation	NULL
(	NULL
1	NULL
,	NULL
14	NULL
,	NULL
26	NULL
,	NULL
63	NULL
)	NULL
.	NULL

The	NULL
Fas-FasL-mediated	NULL
pathway	NULL
of	NULL
apoptosis	NULL
appears	NULL
to	NULL
be	NULL
central	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
peripheral	NULL
tolerance	NULL
,	NULL
because	NULL
mutations	NULL
in	NULL
either	NULL
the	NULL
receptor	NULL
or	NULL
the	NULL
ligand	NULL
can	NULL
induce	NULL
lymph-adenopathy	NULL
and	NULL
autoimmune	NULL
disease	NULL
in	NULL
mice	NULL
and	NULL
humans	NULL
caused	NULL
by	NULL
defects	NULL
in	NULL
AICD	NULL
and	NULL
peripheral	NULL
T-	NULL
and	NULL
B-cell	NULL
deletion	NULL
(	NULL
18	NULL
,	NULL
60	NULL
,	NULL
65	NULL
)	NULL
.	NULL

Fas	NULL
is	NULL
constitutively	NULL
expressed	NULL
on	NULL
most	NULL
cultured	NULL
T	NULL
cells	NULL
,	NULL
whereas	NULL
freshly	NULL
isolated	NULL
,	NULL
naive	NULL
(	NULL
CD4SRO*	NULL
)	NULL
peripheral	NULL
blood	NULL
T	NULL
cells	NULL
have	NULL
little	NULL
to	NULL
no	NULL
surface	NULL
Fas	NULL
.	NULL

Early	NULL
after	NULL
T-cell	NULL
activation	NULL
,	NULL
Fas	NULL
is	NULL
rapidly	NULL
upregulated	NULL
,	NULL
but	NULL
these	NULL
Fas-positive	NULL
cells	NULL
remain	NULL
resistant	NULL
to	NULL
Fas-induced	NULL
apoptosis	NULL
(	NULL
26	NULL
,	NULL
37	NULL
,	NULL
41	NULL
,	NULL
44	NULL
)	NULL
.	NULL

With	NULL
the	NULL
progression	NULL
of	NULL
an	NULL
immune	NULL
response	NULL
,	NULL
Fas-positive	NULL
T	NULL
cells	NULL
acquire	NULL
sensitivity	NULL
to	NULL
Fas-induced	NULL
killing	NULL
(	NULL
37	NULL
,	NULL
44	NULL
)	NULL
.	NULL

Although	NULL
Fas	NULL
upregulation	NULL
is	NULL
known	NULL
to	NULL
be	NULL
a	NULL
prerequisite	NULL
for	NULL
the	NULL
elicitation	NULL
of	NULL
Fas-FasL-mediated	NULL
AICD	NULL
(	NULL
1	NULL
,	NULL
14	NULL
,	NULL
26	NULL
)	NULL
,	NULL
the	NULL
molecular	NULL
mechanisms	NULL
underlying	NULL
this	NULL
process	NULL
have	NULL
not	NULL
been	NULL
well	NULL
investigated	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
the	NULL
imme-	NULL
Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
NF-xB	NULL
__	NULL
«	NULL
B/Sp1	NULL
NF-	NULL
«	NULL
B	NULL
aso	NULL
-C	NULL
u	NULL
L	NULL
WE	NULL
A5	NULL
-	NULL
Lue	NULL
400	NULL
-300	NULL
200	NULL
-100	NULL
__	NULL
NF-	NULL
«	NULL
B	NULL
xB/Sp1	NULL
NF-	NULL
«	NULL
B	NULL
t	NULL
K	NULL
400	NULL
300	NULL
200	NULL
»	NULL
100	NULL
Tg	NULL
Lue	NULL
|	NULL
ASM5.7	NULL
-	NULL
Luc	NULL
NF-xB	NULL
xB/Sp1	NULL
NF-	NULL
«	NULL
B	NULL
—'|—|+_	NULL
Luc	NULL
_|	NULL
A5M5.8	NULL
-	NULL
Luc	NULL
460	NULL
``	NULL
200	NULL
[	NULL
]	NULL
None	NULL
tk	NULL
-	NULL
Lue	NULL
@	NULL
p	NULL
m	NULL
ct	NULL
1-	NULL
GT	NULL
+	NULL
PA	NULL
[	NULL
Lue	NULL
]	NULL
S2tk-	NULL
Luc	NULL
DGT	NULL
+	NULL
P/	NULL
x/SA4tk	NULL
-	NULL
Lue	NULL
oo	NULL
0	NULL
10	NULL
20	NULL
30	NULL
40	NULL
Relative	NULL
Fold	NULL
Induction	NULL
1057	NULL
a	NULL
T	NULL
[	NULL
]	NULL
Vector	NULL
N	NULL
Rsv-isBo	NULL
:	NULL
Relative	NULL
Inhibition	NULL
(	NULL
%	NULL
)	NULL
3	NULL
&	NULL
I	NULL
1	NULL
«	NULL
35-x/S2tk	NULL
x/S4tk	NULL
x/S6tk	NULL
diate	NULL
transcriptional	NULL
events	NULL
and	NULL
cis-acting	NULL
elements	NULL
required	NULL
for	NULL
activation-induced	NULL
fas	NULL
expression	NULL
in	NULL
the	NULL
human	NULL
Jurkat	NULL
cell	NULL
line	NULL
.	NULL

Using	NULL
transient	NULL
transfection	NULL
reporter	NULL
assays	NULL
,	NULL
we	NULL
have	NULL
localized	NULL
a	NULL
47-bp	NULL
sequence	NULL
(	NULL
-306	NULL
to	NULL
-260	NULL
)	NULL
upstream	NULL
of	NULL
the	NULL
translational	NULL
start	NULL
site	NULL
that	NULL
confers	NULL
P/I	NULL
inducibility	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Within	NULL
this	NULL
region	NULL
,	NULL
a	NULL
critical	NULL
10-bp	NULL
enhancer	NULL
(	NULL
-295	NULL
to	NULL
-286	NULL
)	NULL
was	NULL
shown	NULL
to	NULL
bind	NULL
Sp1	NULL
during	NULL
basal	NULL
transcription	NULL
expression	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
p50-p65	NULL
heterodimers	NULL
after	NULL
P/I	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

When	NULL
binding	NULL
of	NULL
NF-kB	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
blockade	NULL
of	NULL
kB	NULL
translocation	NULL
or	NULL
mutagenesis	NULL
of	NULL
the	NULL
site	NULL
,	NULL
activation-dependent	NULL
Fas	NULL
upregulation	NULL
was	NULL
lost	NULL
.	NULL

Our	NULL
findings	NULL
provide	NULL
the	NULL
first	NULL
molecular	NULL
evidence	NULL
for	NULL
differen-	NULL
TRANSCRIPTIONAL	NULL
REGULATION	NULL
OF	NULL
THE	NULL
HUMAN	NULL
f	NULL
@	NULL
s	NULL
PROMOTER	NULL
-	NULL
2105	NULL
Relative	NULL
Fold	NULL
Induction	NULL
5	NULL
10	NULL
15	NULL
20	NULL
[	NULL
]	NULL
None	NULL
®	NULL
P/	NULL
FIG	NULL
.	NULL

6	NULL
.	NULL

The	NULL
«	NULL
B-Sp1	NULL
enhancer	NULL
element	NULL
is	NULL
required	NULL
for	NULL
P/l-inducible	NULL
A5-Luc	NULL
reporter	NULL
activity	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Nucleotide	NULL
mutagenesis	NULL
of	NULL
A5-Luc	NULL
at	NULL
either	NULL
the	NULL
«	NULL
B-Sp1	NULL
element	NULL
(	NULL
GGG-CCC	NULL
;	NULL
-295	NULL
to	NULL
-293	NULL
[	NULL
ASMS5.7-Luc	NULL
]	NULL
)	NULL
or	NULL
the	NULL
downstream	NULL
NF-	NULL
«	NULL
B	NULL
element	NULL
(	NULL
GGG-CCY	NULL
;	NULL
-252	NULL
to	NULL
-249	NULL
[	NULL
A5M5.8-Luc	NULL
]	NULL
)	NULL
was	NULL
introduced	NULL
by	NULL
PCR	NULL
.	NULL

Wild-type	NULL
or	NULL
mutagenized	NULL
constructs	NULL
were	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
with	NULL
10	NULL
ng	NULL
of	NULL
pRL-tk	NULL
,	NULL
and	NULL
the	NULL
cells	NULL
were	NULL
activated	NULL
with	NULL
P/I	NULL
for	NULL
8	NULL
h	NULL
prior	NULL
to	NULL
being	NULL
harvested	NULL
for	NULL
extract	NULL
preparation	NULL
and	NULL
luciferase	NULL
activity	NULL
measurements	NULL
.	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
averages	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
+	NULL
standard	NULL
deviations	NULL
and	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
relative	NULL
fold	NULL
increase	NULL
over	NULL
untreated	NULL
,	NULL
normalized	NULL
A5-Lue	NULL
luciferase	NULL
activity	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Concatemer	NULL
constructs	NULL
containing	NULL
either	NULL
none	NULL
(	NULL
tk-Luc	NULL
)	NULL
,	NULL
two	NULL
(	NULL
x/S2tk-Luc	NULL
)	NULL
,	NULL
four	NULL
(	NULL
x/§4tk-Luc	NULL
)	NULL
,	NULL
or	NULL
six	NULL
(	NULL
x/S6tk-Luc	NULL
)	NULL
copies	NULL
of	NULL
the	NULL
«	NULL
B-Sp1	NULL
element	NULL
(	NULL
-295	NULL
to	NULL
-286	NULL
)	NULL
were	NULL
juxtaposed	NULL
upstream	NULL
of	NULL
a	NULL
thymidine	NULL
kinase-driven	NULL
luciferase	NULL
reporter	NULL
and	NULL
cotransfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
as	NULL
mentioned	NULL
above	NULL
before	NULL
activation	NULL
with	NULL
P/I	NULL
and	NULL
luciferase	NULL
measurements	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
were	NULL
analyzed	NULL
by	NULL
preincubation	NULL
of	NULL
transfected	NULL
cells	NULL
with	NULL
either	NULL
gliotoxin	NULL
(	NULL
GT	NULL
[	NULL
1	NULL
pug/ml	NULL
]	NULL
)	NULL
or	NULL
bis-dethio-bis	NULL
(	NULL
methylthio	NULL
)	NULL
gliotoxin	NULL
(	NULL
DGT	NULL
[	NULL
1	NULL
ug/m1	NULL
]	NULL
)	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

5	NULL
prior	NULL
to	NULL
activation	NULL
with	NULL
P/I	NULL
.	NULL

Relative	NULL
fold	NULL
induction	NULL
is	NULL
calculated	NULL
against	NULL
the	NULL
untreated	NULL
,	NULL
normalized	NULL
tk-Luc	NULL
reporter	NULL
luciferase	NULL
activity	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Specific	NULL
inhibition	NULL
of	NULL
NF-	NULL
«	NULL
B-dependent	NULL
upregulation	NULL
of	NULL
the	NULL
kB-Sp1	NULL
motif	NULL
concatemers	NULL
by	NULL
coexpression	NULL
of	NULL
RsV-IxBa	NULL
.	NULL

Multimerized	NULL
constructs	NULL
were	NULL
cotransfected	NULL
with	NULL
5	NULL
ug	NULL
of	NULL
cither	NULL
RsV-IxBa	NULL
or	NULL
vector-only	NULL
expression	NULL
plasmids	NULL
before	NULL
activation	NULL
with	NULL
P/I	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Extracts	NULL
were	NULL
taken	NULL
for	NULL
luciferase	NULL
measurements	NULL
,	NULL
and	NULL
relative	NULL
inhibition	NULL
is	NULL
calculated	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
P/I-induced	NULL
luciferase	NULL
activity	NULL
of	NULL
the	NULL
corresponding	NULL
reporter	NULL
constructs	NULL
.	NULL

tial	NULL
control	NULL
of	NULL
constitutive	NULL
and	NULL
inducible	NULL
Fas	NULL
expression	NULL
and	NULL
suggest	NULL
an	NULL
intervention	NULL
strategy	NULL
for	NULL
inducible	NULL
Fas	NULL
upregulation	NULL
.	NULL

Spl	NULL
is	NULL
a	NULL
zinc-finger	NULL
transcription	NULL
factor	NULL
constitutively	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
cell	NULL
types	NULL
that	NULL
binds	NULL
the	NULL
GC-rich	NULL
consensus	NULL
sequences	NULL
(	NULL
KGGGCGGRRY	NULL
or	NULL
KRGGCGKRRY	NULL
)	NULL
present	NULL
in	NULL
many	NULL
cellular	NULL
and	NULL
viral	NULL
promoters	NULL
.	NULL

The	NULL
N	NULL
terminus	NULL
of	NULL
Sp1	NULL
contains	NULL
glutamine-	NULL
and	NULL
serine/threonine-rich	NULL
domains	NULL
required	NULL
for	NULL
transactivation	NULL
,	NULL
while	NULL
the	NULL
C	NULL
terminus	NULL
is	NULL
involved	NULL
in	NULL
synergistic	NULL
activation	NULL
and	NULL
interaction	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
(	NULL
12	NULL
)	NULL
.	NULL

Although	NULL
Sp1	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
independently	NULL
initiate	NULL
transcription	NULL
in	NULL
TATA-less	NULL
promoters	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
3	NULL
)	NULL
,	NULL
it	NULL
can	NULL
also	NULL
form	NULL
homo-	NULL
or	NULL
heteromultimeric	NULL
complexes	NULL
to	NULL
transactivate	NULL
a	NULL
number	NULL
of	NULL
disparate	NULL
promoters	NULL
,	NULL
including	NULL
interleukin	NULL
2	NULL
,	NULL
VCAM-1	NULL
,	NULL
and	NULL
the	NULL
HIV	NULL
LTR	NULL
(	NULL
42	NULL
,	NULL
50	NULL
,	NULL
56	NULL
)	NULL
.	NULL

Several	NULL
lines	NULL
of	NULL
circumstantial	NULL
evidence	NULL
suggest	NULL
that	NULL
Spl	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
basal	NULL
fas	NULL
transcription	NULL
.	NULL

First	NULL
,	NULL
sequences	NULL
proximal	NULL
to	NULL
the	NULL
fas	NULL
translational	NULL
start	NULL
site	NULL
have	NULL
a	NULL
relatively	NULL
high	NULL
GC	NULL
content	NULL
(	NULL
61	NULL
%	NULL
between	NULL
positions	NULL
-590	NULL
and	NULL
-1	NULL
)	NULL
and	NULL
an	NULL
absence	NULL
of	NULL
conventional	NULL
TATA	NULL
and	NULL
CAAT	NULL
boxes	NULL
(	NULL
5	NULL
)	NULL
,	NULL
typical	NULL
of	NULL
a	NULL
subclass	NULL
of	NULL
polymerase	NULL
II-dependent	NULL
promoters	NULL
controlled	NULL
by	NULL
the	NULL
interactions	NULL
of	NULL
the	NULL
glutamine-rich	NULL
activation	NULL
domains	NULL
of	NULL
Sp1	NULL
with	NULL
TFIID	NULL
components	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
the	NULL
TATA-less	NULL
,	NULL
GC-rich	NULL
area	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
(	NULL
-590	NULL
to	NULL
-1	NULL
)	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
2106	NULL
CHAN	NULL
ET	NULL
AL	NULL
.	NULL

functional	NULL
in	NULL
analyses	NULL
of	NULL
transcriptional	NULL
start	NULL
sites	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
the	NULL
TATA-less	NULL
A5	NULL
fas	NULL
promoter	NULL
construct	NULL
was	NULL
sufficient	NULL
in	NULL
driving	NULL
basal	NULL
transcription	NULL
.	NULL

Fourth	NULL
,	NULL
Spl	NULL
bound	NULL
to	NULL
the	NULL
kB-Spl	NULL
site	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
in	NULL
resting	NULL
,	NULL
but	NULL
not	NULL
activated	NULL
,	NULL
Jurkat	NULL
cell	NULL
extracts	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
multimers	NULL
of	NULL
the	NULL
kB-Sp1	NULL
element	NULL
at	NULL
positions	NULL
-295	NULL
to	NULL
-286	NULL
showed	NULL
increase	NULL
basal	NULL
transcription	NULL
in	NULL
Jurkat	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

Although	NULL
Sp1	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
control	NULL
of	NULL
fas	NULL
transcription	NULL
in	NULL
resting	NULL
Jurkat	NULL
cells	NULL
,	NULL
it	NULL
is	NULL
likely	NULL
that	NULL
multiple	NULL
Sp1	NULL
binding	NULL
elements	NULL
are	NULL
required	NULL
for	NULL
optimal	NULL
basal	NULL
levels	NULL
of	NULL
Fas	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
site-directed	NULL
mutagenesis	NULL
of	NULL
the	NULL
xB-Sp1	NULL
site	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
alone	NULL
inhibited	NULL
basal	NULL
fas	NULL
transcription	NULL
by	NULL
~20	NULL
%	NULL
,	NULL
while	NULL
disruption	NULL
of	NULL
a	NULL
second	NULL
consensus	NULL
Sp1	NULL
site	NULL
at	NULL
-140	NULL
to	NULL
-131	NULL
repressed	NULL
basal	NULL
fas	NULL
transcription	NULL
by	NULL
greater	NULL
than	NULL
50	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Nuclear	NULL
translocation	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B-Rel	NULL
transcription	NULL
factor	NULL
family	NULL
occurs	NULL
in	NULL
T	NULL
lymphocytes	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
engagement	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
20	NULL
)	NULL
.	NULL

The	NULL
prototypic	NULL
form	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
a	NULL
heterodimer	NULL
complex	NULL
containing	NULL
NF-	NULL
«	NULL
kB1-p50	NULL
or	NULL
NF-	NULL
«	NULL
kB2-p52	NULL
in	NULL
combination	NULL
with	NULL
a	NULL
transactivating	NULL
subunit	NULL
such	NULL
as	NULL
c-Rel	NULL
or	NULL
RelA	NULL
(	NULL
p65	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
64	NULL
)	NULL
.	NULL

Each	NULL
NF-	NULL
«	NULL
xB-Rel	NULL
family	NULL
member	NULL
contains	NULL
a	NULL
conserved	NULL
N-terminal	NULL
region	NULL
responsible	NULL
for	NULL
decameric	NULL
DNA	NULL
binding	NULL
,	NULL
dimerization	NULL
,	NULL
and	NULL
IxB	NULL
interaction	NULL
;	NULL
NF-	NULL
«	NULL
B-responsive	NULL
genes	NULL
are	NULL
transacti-vated	NULL
by	NULL
the	NULL
C-terminal	NULL
domain	NULL
of	NULL
dimeric	NULL
NF-	NULL
«	NULL
B-Rel	NULL
family	NULL
members	NULL
.	NULL

In	NULL
resting	NULL
T	NULL
lymphocytes	NULL
,	NULL
various	NULL
NF-	NULL
«	NULL
B	NULL
subunits	NULL
are	NULL
sequestered	NULL
in	NULL
the	NULL
cytoplasm	NULL
by	NULL
virtue	NULL
of	NULL
their	NULL
association	NULL
with	NULL
by	NULL
the	NULL
IxB	NULL
family	NULL
of	NULL
inhibitors	NULL
(	NULL
IxBa	NULL
,	NULL
IxBB	NULL
,	NULL
IxBg	NULL
,	NULL
IxBy	NULL
,	NULL
and	NULL
bel-3	NULL
)	NULL
,	NULL
which	NULL
masks	NULL
their	NULL
nuclear	NULL
localization	NULL
signal	NULL
(	NULL
reviewed	NULL
in	NULL
reference	NULL
64	NULL
)	NULL
.	NULL

During	NULL
T-cell	NULL
activation	NULL
,	NULL
intracellular	NULL
signaling	NULL
triggers	NULL
multiple	NULL
kinase	NULL
pathways	NULL
that	NULL
converge	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
IxB	NULL
kinase	NULL
complex	NULL
(	NULL
IKK	NULL
)	NULL
;	NULL
IKK	NULL
then	NULL
phos-phorylates	NULL
IxBa	NULL
or	NULL
IxBB	NULL
at	NULL
conserved	NULL
serines	NULL
,	NULL
resulting	NULL
in	NULL
the	NULL
targeting	NULL
of	NULL
the	NULL
kB	NULL
inhibitor	NULL
for	NULL
ubiquitin-proteasome-depen-dent	NULL
destruction	NULL
and	NULL
permitting	NULL
the	NULL
nuclear	NULL
translocation	NULL
of	NULL
NF-kB	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Binding	NULL
sites	NULL
for	NULL
NF-kB	NULL
have	NULL
been	NULL
found	NULL
in	NULL
numerous	NULL
genes	NULL
involved	NULL
in	NULL
effector	NULL
T-cell	NULL
function	NULL
,	NULL
including	NULL
those	NULL
regulating	NULL
cytokine	NULL
production	NULL
,	NULL
cell	NULL
adhesion	NULL
molecules	NULL
,	NULL
and	NULL
apoptosis	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
have	NULL
demonstrated	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
p50-p65	NULL
mediates	NULL
inducible	NULL
fas	NULL
promoter	NULL
activation	NULL
in	NULL
T	NULL
lymphocytes	NULL
at	NULL
-460	NULL
to	NULL
-240	NULL
and	NULL
confers	NULL
the	NULL
majority	NULL
of	NULL
P/I	NULL
responsiveness	NULL
at	NULL
a	NULL
single	NULL
,	NULL
noncanonical	NULL
<	NULL
B-Spl-like	NULL
motif	NULL
(	NULL
GGGCGTTCCC	NULL
)	NULL
located	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
.	NULL

Interestingly	NULL
,	NULL
although	NULL
two	NULL
consensus	NULL
NF-KB	NULL
sites	NULL
as	NULL
well	NULL
as	NULL
GAS	NULL
,	NULL
NF-ATp	NULL
,	NULL
AP-2	NULL
,	NULL
and	NULL
Egr-1	NULL
sites	NULL
are	NULL
also	NULL
present	NULL
within	NULL
this	NULL
region	NULL
,	NULL
the	NULL
contribution	NULL
of	NULL
these	NULL
elements	NULL
to	NULL
either	NULL
basal	NULL
or	NULL
inducible	NULL
fas	NULL
promoter	NULL
induction	NULL
in	NULL
Jurkat	NULL
cells	NULL
was	NULL
insignificant	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Notably	NULL
,	NULL
however	NULL
,	NULL
such	NULL
motifs	NULL
may	NULL
be	NULL
functional	NULL
in	NULL
other	NULL
cell	NULL
types	NULL
,	NULL
because	NULL
Egr-1	NULL
binding	NULL
at	NULL
-371	NULL
to	NULL
-338	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
repress	NULL
fas	NULL
transcription	NULL
during	NULL
B-cell	NULL
activation	NULL
(	NULL
16	NULL
)	NULL
.	NULL

The	NULL
mutually	NULL
exclusive	NULL
binding	NULL
of	NULL
either	NULL
Spl	NULL
or	NULL
NF-kB	NULL
to	NULL
the	NULL
novel	NULL
composite	NULL
<	NULL
B-Sp1	NULL
site	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
in	NULL
the	NULL
fas	NULL
promoter	NULL
differs	NULL
from	NULL
the	NULL
previously	NULL
described	NULL
cross-coupling	NULL
of	NULL
NF-kB	NULL
with	NULL
the	NULL
transcription	NULL
factor	NULL
AP-1	NULL
or	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
(	NULL
58	NULL
,	NULL
62	NULL
)	NULL
.	NULL

Our	NULL
observations	NULL
are	NULL
not	NULL
unexpected	NULL
,	NULL
however	NULL
,	NULL
in	NULL
light	NULL
of	NULL
reports	NULL
documenting	NULL
the	NULL
functional	NULL
interference	NULL
of	NULL
Spl	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
at	NULL
selected	NULL
NF-kB	NULL
binding	NULL
sites	NULL
(	NULL
21	NULL
)	NULL
and	NULL
crystallographic	NULL
data	NULL
showing	NULL
that	NULL
Sp1	NULL
and	NULL
p50	NULL
homodimers	NULL
both	NULL
interact	NULL
with	NULL
DNA	NULL
at	NULL
the	NULL
major	NULL
groove	NULL
(	NULL
19	NULL
,	NULL
38	NULL
,	NULL
49	NULL
)	NULL
.	NULL

In	NULL
this	NULL
report	NULL
,	NULL
we	NULL
provide	NULL
multiple	NULL
lines	NULL
of	NULL
evidence	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
p50-p65	NULL
heterodimers	NULL
displace	NULL
Sp1	NULL
at	NULL
the	NULL
composite	NULL
kB-Sp1	NULL
site	NULL
to	NULL
drive	NULL
activation-dependent	NULL
interaction	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
.	NULL

First	NULL
,	NULL
P/I-dependent	NULL
promoter	NULL
induction	NULL
requires	NULL
the	NULL
sequences	NULL
between	NULL
-306	NULL
and	NULL
-260	NULL
containing	NULL
the	NULL
kB-Sp1l	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
.	NULL

Second	NULL
,	NULL
NF-kB	NULL
p50-65	NULL
heterodimers	NULL
bound	NULL
to	NULL
this	NULL
region	NULL
of	NULL
the	NULL
fas	NULL
promoter	NULL
only	NULL
during	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Third	NULL
,	NULL
recombinant	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
displaced	NULL
Sp1	NULL
binding	NULL
to	NULL
Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

the	NULL
xB-Sp1	NULL
site	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

4C	NULL
)	NULL
.	NULL

Fourth	NULL
,	NULL
recruitment	NULL
of	NULL
NF-kB	NULL
to	NULL
the	NULL
fas	NULL
promoter	NULL
region	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
was	NULL
required	NULL
for	NULL
activation-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
,	NULL
but	NULL
not	NULL
for	NULL
basal	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Fifth	NULL
,	NULL
specific	NULL
mutagenesis	NULL
of	NULL
the	NULL
NF-kB	NULL
site	NULL
at	NULL
-295	NULL
to	NULL
-286	NULL
significantly	NULL
diminished	NULL
P/I-dependent	NULL
fas	NULL
promoter	NULL
induction	NULL
(	NULL
Fig	NULL
.	NULL

6A	NULL
)	NULL
.	NULL

Finally	NULL
,	NULL
multimers	NULL
of	NULL
the	NULL
«	NULL
B-Sp1	NULL
site	NULL
juxtaposed	NULL
to	NULL
a	NULL
minimal	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
were	NULL
functionally	NULL
responsive	NULL
to	NULL
P/I	NULL
stimulation	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
(	NULL
Fig	NULL
.	NULL

6B	NULL
)	NULL
.	NULL

In	NULL
further	NULL
support	NULL
of	NULL
our	NULL
observations	NULL
that	NULL
NF-	NULL
«	NULL
B	NULL
is	NULL
critically	NULL
required	NULL
for	NULL
activation-induced	NULL
fas	NULL
upregulation	NULL
,	NULL
several	NULL
inducers	NULL
of	NULL
NF-kB	NULL
,	NULL
including	NULL
UV	NULL
irradiation	NULL
,	NULL
hypoxia	NULL
,	NULL
cytokines	NULL
,	NULL
and	NULL
TNF	NULL
,	NULL
have	NULL
been	NULL
reported	NULL
to	NULL
rapidly	NULL
upregulate	NULL
Fas	NULL
(	NULL
24	NULL
,	NULL
44	NULL
,	NULL
61	NULL
)	NULL
.	NULL

It	NULL
is	NULL
interesting	NULL
to	NULL
speculate	NULL
that	NULL
Sp1	NULL
,	NULL
bound	NULL
to	NULL
the	NULL
kB-Sp1	NULL
site	NULL
during	NULL
basal	NULL
transcription	NULL
,	NULL
may	NULL
facilitate	NULL
rapid	NULL
activation-induced	NULL
fas	NULL
promoter	NULL
responsiveness	NULL
mediated	NULL
by	NULL
NF-kB	NULL
translocation	NULL
as	NULL
a	NULL
consequence	NULL
of	NULL
its	NULL
role	NULL
in	NULL
DNA	NULL
bending	NULL
(	NULL
57	NULL
)	NULL
.	NULL

If	NULL
Fas	NULL
is	NULL
similarly	NULL
regulated	NULL
in	NULL
Jurkat	NULL
and	NULL
fresh	NULL
T	NULL
cells	NULL
,	NULL
our	NULL
findings	NULL
may	NULL
be	NULL
relevant	NULL
to	NULL
HIV	NULL
pathogenesis	NULL
,	NULL
in	NULL
which	NULL
increased	NULL
Fas	NULL
expression	NULL
and	NULL
sensitivity	NULL
to	NULL
FasL-induced	NULL
apoptosis	NULL
have	NULL
been	NULL
reported	NULL
during	NULL
infection	NULL
and	NULL
disease	NULL
progression	NULL
(	NULL
2	NULL
,	NULL
4	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Interestingly	NULL
,	NULL
both	NULL
HIV-1	NULL
binding	NULL
and	NULL
gp120-mediated	NULL
CD4	NULL
cross-linking	NULL
can	NULL
induce	NULL
NF-kB	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Because	NULL
NF-kB	NULL
can	NULL
drive	NULL
both	NULL
HIV-1	NULL
expression	NULL
(	NULL
50	NULL
)	NULL
and	NULL
fas	NULL
upregulation	NULL
,	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
may	NULL
be	NULL
one	NULL
major	NULL
strategy	NULL
to	NULL
suppress	NULL
both	NULL
viral	NULL
replication	NULL
(	NULL
31	NULL
)	NULL
and	NULL
premature	NULL
execution	NULL
of	NULL
the	NULL
AICD	NULL
pathway	NULL
resulting	NULL
in	NULL
T-cell	NULL
depletion	NULL
.	NULL

Indeed	NULL
,	NULL
inhibitors	NULL
of	NULL
NF-kB	NULL
may	NULL
also	NULL
effectively	NULL
repress	NULL
Fas-driven	NULL
apoptosis	NULL
in	NULL
response	NULL
to	NULL
metabolic	NULL
stress	NULL
,	NULL
genotoxic	NULL
insults	NULL
,	NULL
and	NULL
viral	NULL
infections	NULL
.	NULL

Although	NULL
our	NULL
studies	NULL
clearly	NULL
demonstrate	NULL
a	NULL
critical	NULL
role	NULL
for	NULL
NF-	NULL
«	NULL
B	NULL
in	NULL
fas	NULL
upregulation	NULL
,	NULL
other	NULL
transcriptional	NULL
or	NULL
posttran-scriptional	NULL
processes	NULL
may	NULL
also	NULL
be	NULL
operative	NULL
,	NULL
depending	NULL
upon	NULL
the	NULL
cell	NULL
type	NULL
and	NULL
cellular	NULL
microenvironment	NULL
.	NULL

For	NULL
example	NULL
,	NULL
the	NULL
proline-	NULL
,	NULL
glutamine-	NULL
,	NULL
and	NULL
histidine-rich	NULL
protein	NULL
TDAGS1	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
Fas	NULL
mRNA	NULL
induction	NULL
after	NULL
TCR	NULL
engagement	NULL
(	NULL
47	NULL
)	NULL
.	NULL

Our	NULL
laboratory	NULL
has	NULL
demonstrated	NULL
that	NULL
wild-type	NULL
p53	NULL
can	NULL
upregulate	NULL
fas	NULL
expression	NULL
in	NULL
both	NULL
hematopoietic	NULL
and	NULL
nonhematopoietic	NULL
cells	NULL
(	NULL
45	NULL
)	NULL
.	NULL

Taken	NULL
with	NULL
our	NULL
current	NULL
observations	NULL
,	NULL
it	NULL
is	NULL
plausible	NULL
that	NULL
p53	NULL
may	NULL
act	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
to	NULL
increase	NULL
fas	NULL
transcription	NULL
,	NULL
particularly	NULL
under	NULL
conditions	NULL
of	NULL
metabolic	NULL
and	NULL
genotoxic	NULL
stress	NULL
.	NULL

mRNA	NULL
stability	NULL
may	NULL
also	NULL
regulate	NULL
fas	NULL
expression	NULL
.	NULL

In	NULL
this	NULL
regard	NULL
,	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
fas	NULL
contains	NULL
several	NULL
AU-rich	NULL
elements	NULL
reported	NULL
to	NULL
induce	NULL
selective	NULL
mRNA	NULL
degradation	NULL
(	NULL
29	NULL
,	NULL
55	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
potent	NULL
biological	NULL
function	NULL
of	NULL
the	NULL
Fas	NULL
protein	NULL
,	NULL
multiple	NULL
levels	NULL
of	NULL
gene	NULL
regulation	NULL
involving	NULL
both	NULL
cis-acting	NULL
transcription	NULL
and	NULL
mRNA	NULL
stability	NULL
would	NULL
not	NULL
be	NULL
unexpected	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
studies	NULL
have	NULL
identified	NULL
a	NULL
novel	NULL
kB-Spl	NULL
enhancer	NULL
motif	NULL
in	NULL
the	NULL
fas	NULL
promoter	NULL
in	NULL
which	NULL
NF-kB	NULL
p50-p65	NULL
dimers	NULL
bind	NULL
to	NULL
drive	NULL
activation-dependent	NULL
Fas	NULL
upregulation	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

The	NULL
critical	NULL
involvement	NULL
of	NULL
NF-kB	NULL
further	NULL
underscores	NULL
the	NULL
importance	NULL
of	NULL
this	NULL
transcription	NULL
factor	NULL
in	NULL
immuno-homeostasis	NULL
and	NULL
prompts	NULL
consideration	NULL
for	NULL
strategies	NULL
aimed	NULL
toward	NULL
its	NULL
manipulation	NULL
in	NULL
various	NULL
pathophysiological	NULL
states	NULL
involving	NULL
inappropriate	NULL
Fas	NULL
and	NULL
FasL	NULL
interactions	NULL
,	NULL
including	NULL
malignant	NULL
disease	NULL
,	NULL
autoimmunity	NULL
,	NULL
and	NULL
AIDS	NULL
.	NULL

ACKNOWLEDGMENTS	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
NIH	NULL
Cancer	NULL
Center	NULL
Support	NULL
Core	NULL
grant	NULL
CA16672	NULL
,	NULL
NIH	NULL
predoctoral	NULL
fellowship	NULL
(	NULL
H.C.	NULL
)	NULL
,	NULL
and	NULL
American	NULL
Cancer	NULL
Society	NULL
grant	NULL
CIM	NULL
88929	NULL
(	NULL
L.B.O.-S.	NULL
)	NULL
.	NULL

We	NULL
thank	NULL
Karen	NULL
Ramirez	NULL
for	NULL
providing	NULL
technical	NULL
expertise	NULL
with	NULL
flow	NULL
cytometric	NULL
analyses	NULL
and	NULL
Kathleen	NULL
McAveney	NULL
and	NULL
David	NULL
McConkey	NULL
for	NULL
critical	NULL
reading	NULL
of	NULL
the	NULL
manuscript	NULL
.	NULL

Vor	NULL
.	NULL

19	NULL
,	NULL
1999	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

REFERENCES	NULL
.	NULL

Alderson	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
T.	NULL
W.	NULL
Tough	NULL
,	NULL
T.	NULL
Davis-Smith	NULL
,	NULL
S.	NULL
Braddy	NULL
,	NULL
B.	NULL
Falk	NULL
,	NULL
K.	NULL
A.	NULL
Schooley	NULL
,	NULL
R.	NULL
G.	NULL
Goodwin	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
F.	NULL
Ramsdell	NULL
,	NULL
and	NULL
D.	NULL
H.	NULL
Lynch	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
ligand	NULL
mediates	NULL
activation-induced	NULL
cell	NULL
death	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:71-77.	NULL
.	NULL

Aries	NULL
,	NULL
S.	NULL
,	NULL
B.	NULL
Scgaaf	NULL
,	NULL
C.	NULL
Muller	NULL
,	NULL
R.	NULL
Dennin	NULL
,	NULL
and	NULL
K.	NULL
Dalhoff	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
expression	NULL
of	NULL
CD4*	NULL
T	NULL
cells	NULL
from	NULL
HIV-infected	NULL
patients	NULL
increases	NULL
with	NULL
dis-case	NULL
progression	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Med	NULL
.	NULL

73:591-593.	NULL
.	NULL

Azizkhan	NULL
,	NULL
J.	NULL
C.	NULL
,	NULL
D.	NULL
E.	NULL
Jensen	NULL
,	NULL
A.	NULL
J	NULL
.	NULL

Pierce	NULL
,	NULL
and	NULL
M.	NULL
Wade	NULL
.	NULL

1993	NULL
.	NULL

Transcription	NULL
from	NULL
TATA-less	NULL
promoters	NULL
:	NULL
dihydrofolate	NULL
reductase	NULL
as	NULL
a	NULL
model	NULL
.	NULL

Crit	NULL
.	NULL

Rev	NULL
.	NULL

Eukaryot	NULL
.	NULL

Gene	NULL
Expr	NULL
.	NULL

3:229-254.	NULL
.	NULL

Banda	NULL
,	NULL
N.	NULL
K.	NULL
,	NULL
J.	NULL
Bernier	NULL
,	NULL
D.	NULL
K.	NULL
Kurabara	NULL
,	NULL
R.	NULL
Kurrie	NULL
,	NULL
N.	NULL
Haligwood	NULL
,	NULL
R.	NULL
P.	NULL
Sekaly	NULL
,	NULL
and	NULL
T.	NULL
H.	NULL
Finkel	NULL
.	NULL

1992	NULL
.	NULL

Crosslinking	NULL
CD4	NULL
by	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
gp120	NULL
primes	NULL
T	NULL
cells	NULL
for	NULL
activation-induced	NULL
apoptosis	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

176:1099-1106.	NULL
.	NULL

Behrmann	NULL
,	NULL
L	NULL
,	NULL
H.	NULL
Walczak	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1994	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
human	NULL
APO-1	NULL
gene	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:3057-3062.	NULL
.	NULL

Boise	NULL
,	NULL
L.	NULL
H.	NULL
,	NULL
A.	NULL
J.	NULL
Minn	NULL
,	NULL
P.	NULL
J.	NULL
Noel	NULL
,	NULL
C.	NULL
H.	NULL
June	NULL
,	NULL
M.	NULL
A.	NULL
Accavitti	NULL
,	NULL
T.	NULL
Lindsten	NULL
,	NULL
and	NULL
C.	NULL
B.	NULL
Thompson	NULL
.	NULL

1995	NULL
.	NULL

CD28	NULL
costimulation	NULL
can	NULL
promote	NULL
T	NULL
cell	NULL
survival	NULL
by	NULL
enhancing	NULL
the	NULL
expression	NULL
of	NULL
Bcl-x	NULL
,	NULL
Immunity	NULL
3:87-98.	NULL
.	NULL

Boldin	NULL
,	NULL
M.	NULL
P.	NULL
,	NULL
T.	NULL
M.	NULL
G.	NULL
Goncharou	NULL
,	NULL
Y.	NULL
V.	NULL
Goltsev	NULL
,	NULL
and	NULL
D.	NULL
Wallach	NULL
.	NULL

1996	NULL
.	NULL

Involvement	NULL
of	NULL
MACH1	NULL
,	NULL
a	NULL
novel	NULL
MORT1/FADD	NULL
interacting	NULL
protease	NULL
,	NULL
in	NULL
Fas/APO-1	NULL
and	NULL
TNF	NULL
receptor-induced	NULL
cell	NULL
death	NULL
.	NULL

Cell	NULL
85:803-815.	NULL
.	NULL

Briant	NULL
,	NULL
L.	NULL
,	NULL
N.	NULL
Coudronniere	NULL
,	NULL
V.	NULL
Hebmann-Robert	NULL
,	NULL
M.	NULL
Benkirane	NULL
,	NULL
and	NULL
C.	NULL
Devaux	NULL
.	NULL

1996	NULL
.	NULL

Binding	NULL
of	NULL
HIV-1	NULL
virions	NULL
or	NULL
gp120-anti-gp120	NULL
immune	NULL
complexes	NULL
to	NULL
HIV-1-infected	NULL
quiescent	NULL
peripheral	NULL
blood	NULL
mononuclear	NULL
cells	NULL
reveals	NULL
latent	NULL
infection	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

156:3994-4004.	NULL
.	NULL

Chen	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
L.	NULL
D.	NULL
Attardi	NULL
,	NULL
C.	NULL
P.	NULL
Verrijzer	NULL
,	NULL
K.	NULL
Yokomori	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1994	NULL
.	NULL

Assembly	NULL
of	NULL
recombinant	NULL
TFIID	NULL
reveals	NULL
differential	NULL
coactivator	NULL
requirements	NULL
for	NULL
distinct	NULL
transcriptional	NULL
activators	NULL
.	NULL

Cell	NULL
79:93-105	NULL
.	NULL

Chen	NULL
,	NULL
Z.	NULL
,	NULL
J.	NULL
P.	NULL
Hagler	NULL
,	NULL
V.	NULL
F.	NULL
Melandri	NULL
,	NULL
B.	NULL
D.	NULL
Scherer	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1995	NULL
.	NULL

Signal-induced	NULL
site-specific	NULL
phosphorylation	NULL
targets	NULL
IxBa	NULL
«	NULL
to	NULL
the	NULL
ubiquitin-proteasome	NULL
pathway	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:1586-1597	NULL
.	NULL

Chodish	NULL
,	NULL
L.	NULL
A	NULL
.	NULL

1989	NULL
.	NULL

DNA-protein	NULL
interactions	NULL
,	NULL
p.	NULL
12.2.1-12.2.10	NULL
,	NULL
In	NULL
F.	NULL
M.	NULL
Ausubel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
ed	NULL
.	NULL
)	NULL

,	NULL
Current	NULL
protocols	NULL
in	NULL
molecular	NULL
biology	NULL
,	NULL
vol	NULL
.	NULL

2	NULL
.	NULL

Greene	NULL
Publishing	NULL
Associates	NULL
and	NULL
Wiley-Interscience	NULL
,	NULL
New	NULL
York	NULL
,	NULL
N.Y.	NULL
Courey	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
D.	NULL
A.	NULL
Holtzman	NULL
,	NULL
S.	NULL
P.	NULL
Jackson	NULL
,	NULL
and	NULL
R.	NULL
Tjian	NULL
.	NULL

1989	NULL
.	NULL

Synergistic	NULL
activation	NULL
by	NULL
the	NULL
glutamine-rich	NULL
domains	NULL
of	NULL
human	NULL
transcription	NULL
factor	NULL
Sp1	NULL
.	NULL

Cell	NULL
59:827-836	NULL
.	NULL

Debatin	NULL
,	NULL
K.-M.	NULL
,	NULL
D.	NULL
Siiss	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1994	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
APO-1	NULL
on	NULL
human	NULL
thymocytes	NULL
:	NULL
implications	NULL
for	NULL
negative	NULL
selection	NULL
?	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

24:753-758	NULL
.	NULL

Dhein	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Walczak	NULL
,	NULL
C.	NULL
Baumler	NULL
,	NULL
K.	NULL
M.	NULL
Debatin	NULL
,	NULL
and	NULL
P.	NULL
H.	NULL
Krammer	NULL
.	NULL

1995	NULL
.	NULL

Autocrine	NULL
T-cell	NULL
suicide	NULL
mediated	NULL
by	NULL
APO-1/	NULL
(	NULL
Fas/CD95	NULL
)	NULL
.	NULL

Nature	NULL
373	NULL
:	NULL
438-441	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
,	NULL
R.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

Dinkel	NULL
,	NULL
A.	NULL
,	NULL
W.	NULL
K.	NULL
Aicher	NULL
,	NULL
C.	NULL
Haas	NULL
,	NULL
P.	NULL
F.	NULL
Zipfel	NULL
,	NULL
H.-H.	NULL
Peter	NULL
,	NULL
and	NULL
H.	NULL
Eibel	NULL
.	NULL

1997	NULL
.	NULL

Transcription	NULL
factor	NULL
Egr-1	NULL
activity	NULL
down-regulates	NULL
Fas	NULL
and	NULL
CD23	NULL
expression	NULL
in	NULL
B	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

159:2678-2684	NULL
.	NULL

Drappa	NULL
,	NULL
J.	NULL
,	NULL
N.	NULL
Brot	NULL
,	NULL
and	NULL
K.	NULL
B.	NULL
Elkon	NULL
.	NULL

1993	NULL
.	NULL

The	NULL
Fas	NULL
protein	NULL
is	NULL
expressed	NULL
at	NULL
high	NULL
levels	NULL
on	NULL
€CD4+CD8+	NULL
thymocytes	NULL
and	NULL
activated	NULL
mature	NULL
lymphocytes	NULL
in	NULL
normal	NULL
mice	NULL
but	NULL
not	NULL
in	NULL
the	NULL
lupus-prone	NULL
strain	NULL
,	NULL
MRL	NULL
/pr/lpr	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:10340-10344	NULL
.	NULL

Fisher	NULL
,	NULL
G.	NULL
H.	NULL
,	NULL
F.	NULL
J.	NULL
Rosenberg	NULL
,	NULL
S.	NULL
E.	NULL
Straus	NULL
,	NULL
J.	NULL
K.	NULL
Dale	NULL
,	NULL
L.	NULL
A.	NULL
Middleton	NULL
,	NULL
A.	NULL
Y.	NULL
Lin	NULL
,	NULL
W.	NULL
Strober	NULL
,	NULL
M.	NULL
J.	NULL
Lenardo	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Puck	NULL
.	NULL

1995	NULL
.	NULL

Dominant	NULL
interfering	NULL
Fas	NULL
gene	NULL
mutations	NULL
impair	NULL
apoptosis	NULL
in	NULL
a	NULL
human	NULL
autoimmune	NULL
lymphoproliferative	NULL
syndrome	NULL
.	NULL

Cell	NULL
81:935-946	NULL
.	NULL

Ghosh	NULL
,	NULL
G.	NULL
,	NULL
G.	NULL
V.	NULL
Duyne	NULL
,	NULL
S.	NULL
Ghosh	NULL
,	NULL
and	NULL
P.	NULL
B.	NULL
Sigler	NULL
.	NULL

1995	NULL
.	NULL

Structure	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
p50	NULL
homodimer	NULL
bound	NULL
to	NULL
a	NULL
«	NULL
B	NULL
site	NULL
.	NULL

Nature	NULL
373:303-310	NULL
.	NULL

Ghosh	NULL
,	NULL
S.	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

May	NULL
,	NULL
and	NULL
E.	NULL
B.	NULL
Kopp	NULL
.	NULL

1998	NULL
.	NULL

NF-	NULL
«	NULL
B	NULL
and	NULL
Rel	NULL
proteins	NULL
:	NULL
evolutionarily	NULL
conserved	NULL
mediators	NULL
of	NULL
immune	NULL
responses	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

16:225-260	NULL
.	NULL

Hirano	NULL
,	NULL
F.	NULL
,	NULL
H.	NULL
Tanaka	NULL
,	NULL
Y.	NULL
Hirano	NULL
,	NULL
M.	NULL
Hiramoto	NULL
,	NULL
H.	NULL
Handa	NULL
,	NULL
I.	NULL
Makino	NULL
,	NULL
and	NULL
C.	NULL
Scheidereit	NULL
.	NULL

1998	NULL
.	NULL

Functional	NULL
interference	NULL
of	NULL
Sp1	NULL
and	NULL
NF-	NULL
«	NULL
B	NULL
through	NULL
the	NULL
same	NULL
DNA	NULL
binding	NULL
site	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18:1266-1274	NULL
.	NULL

Irmler	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Thome	NULL
,	NULL
M.	NULL
Hahne	NULL
,	NULL
P.	NULL
Schneider	NULL
,	NULL
K.	NULL
Hofmann	NULL
,	NULL
V.	NULL
Steiner	NULL
,	NULL
J.-L.	NULL
Bodmer	NULL
,	NULL
M.	NULL
Schriter	NULL
,	NULL
K.	NULL
Burns	NULL
,	NULL
C.	NULL
Mattmann	NULL
,	NULL
D.	NULL
Rimoldi	NULL
,	NULL
L.	NULL
E.	NULL
French	NULL
,	NULL
and	NULL
J.	NULL
Tschopp	NULL
.	NULL

1997	NULL
.	NULL

Inhibition	NULL
of	NULL
death	NULL
receptor	NULL
signals	NULL
by	NULL
cellular	NULL
FLIP	NULL
.	NULL

Nature	NULL
388:190-195	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
Y.	NULL
Tsujimoto	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1993	NULL
.	NULL

Effect	NULL
of	NULL
bel-2	NULL
on	NULL
Fas	NULL
antigen-mediated	NULL
cell	NULL
death	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

151:621-627	NULL
.	NULL

Itoh	NULL
,	NULL
N.	NULL
,	NULL
S.	NULL
Yonehara	NULL
,	NULL
A.	NULL
Ishii	NULL
,	NULL
M.	NULL
Yonebara	NULL
,	NULL
S.	NULL
Mizushima	NULL
,	NULL
M.	NULL
Sameshima	NULL
,	NULL
A.	NULL
Hase	NULL
,	NULL
Y.	NULL
Seto	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1991	NULL
.	NULL

The	NULL
polypeptide	NULL
encoded	NULL
by	NULL
the	NULL
cDNA	NULL
for	NULL
human	NULL
cell	NULL
surface	NULL
antigen	NULL
Fas	NULL
can	NULL
mediate	NULL
apoptosis	NULL
.	NULL

Cell	NULL
66	NULL
:	NULL
233-243	NULL
.	NULL

Jiiittela	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Benedict	NULL
,	NULL
M.	NULL
Tewari	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Shayman	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1995	NULL
.	NULL

Bcl-x	NULL
and	NULL
bel-2	NULL
inhibit	NULL
TNF	NULL
and	NULL
Fas-induced	NULL
apoptosis	NULL
and	NULL
activation	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
in	NULL
breast	NULL
carcinoma	NULL
cells	NULL
.	NULL

Oncogene	NULL
10:2297-2305	NULL
.	NULL

Ju	NULL
,	NULL
S.	NULL
T.	NULL
,	NULL
D.	NULL
J.	NULL
Panka	NULL
,	NULL
H.	NULL
Cul	NULL
,	NULL
R.	NULL
Ettinger	NULL
,	NULL
M.	NULL
El-Kbatib	NULL
,	NULL
D.	NULL
H.	NULL
Sherr	NULL
,	NULL
B	NULL
.	NULL

Z.	NULL
Stanger	NULL
,	NULL
and	NULL
A.	NULL
Marshak-Rothstein	NULL
.	NULL

1995	NULL
.	NULL

Fas	NULL
(	NULL
CD95	NULL
)	NULL
/FasL	NULL
interactions	NULL
TRANSCRIPTIONAL	NULL
REGULATION	NULL
OF	NULL
THE	NULL
HUMAN	NULL
fas	NULL
PROMOTER	NULL
27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41.	NULL
.	NULL

Neish	NULL
,	NULL
A.	NULL
S.	NULL
,	NULL
L.	NULL
M.	NULL
Khachigian	NULL
,	NULL
A	NULL
.	NULL

Park	NULL
,	NULL
V.	NULL
R.	NULL
Baichwal	NULL
,	NULL
and	NULL
T.	NULL
Collins	NULL
.	NULL

1995	NULL
.	NULL

43	NULL
.	NULL

44	NULL
.	NULL

45	NULL
.	NULL

46	NULL
.	NULL

47	NULL
.	NULL

48	NULL
.	NULL

49	NULL
.	NULL

50	NULL
.	NULL

2107	NULL
required	NULL
for	NULL
programmed	NULL
cell	NULL
death	NULL
after	NULL
T-cell	NULL
activation	NULL
.	NULL

Nature	NULL
373:444-448	NULL
.	NULL

Katsikis	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
E.	NULL
S.	NULL
Wunderlich	NULL
,	NULL
C.	NULL
A.	NULL
Smith	NULL
,	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
,	NULL
and	NULL
L.	NULL
A.	NULL
Herzenberg	NULL
,	NULL
1995	NULL
.	NULL

Fas	NULL
antigen	NULL
stimulation	NULL
induces	NULL
marked	NULL
apoptosis	NULL
of	NULL
T	NULL
lymphocytes	NULL
in	NULL
human	NULL
immunodeficiency	NULL
virus-infected	NULL
individuals	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

181:2029-2036	NULL
.	NULL

Kemper	NULL
,	NULL
O.	NULL
,	NULL
and	NULL
D.	NULL
Wallach	NULL
.	NULL

1993	NULL
.	NULL

Cloning	NULL
and	NULL
partial	NULL
characterization	NULL
of	NULL
the	NULL
promoter	NULL
for	NULL
the	NULL
human	NULL
p35	NULL
tumor	NULL
necrosis	NULL
factor	NULL
(	NULL
INF	NULL
)	NULL
receptor	NULL
.	NULL

Gene	NULL
134:209-216	NULL
.	NULL

Kruys	NULL
,	NULL
V.	NULL
,	NULL
O.	NULL
Marinx	NULL
,	NULL
G.	NULL
Shaw	NULL
,	NULL
J.	NULL
Deschamps	NULL
,	NULL
and	NULL
G.	NULL
Huez	NULL
.	NULL

1989	NULL
.	NULL

Translational	NULL
blockade	NULL
imposed	NULL
by	NULL
cytokine-derived	NULL
UA-rich	NULL
sequences	NULL
.	NULL

Science	NULL
245:852-855	NULL
.	NULL

Kunsch	NULL
,	NULL
C.	NULL
,	NULL
S.	NULL
M.	NULL
Ruben	NULL
,	NULL
and	NULL
C.	NULL
A.	NULL
Rosen	NULL
.	NULL

1992	NULL
.	NULL

Selection	NULL
of	NULL
optimal	NULL
«	NULL
xB/Rel	NULL
DNA-binding	NULL
motifs	NULL
:	NULL
interaction	NULL
of	NULL
both	NULL
subunits	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
with	NULL
DNA	NULL
is	NULL
required	NULL
for	NULL
transcriptional	NULL
activation	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:4412-4421	NULL
.	NULL

Kwon	NULL
,	NULL
H.	NULL
,	NULL
N.	NULL
Pelletier	NULL
,	NULL
C.	NULL
DeLuca	NULL
,	NULL
P.	NULL
Genin	NULL
,	NULL
S.	NULL
Cisternas	NULL
,	NULL
R.	NULL
Lin	NULL
,	NULL
M.	NULL
A.	NULL
Wainberg	NULL
,	NULL
and	NULL
J.	NULL
Hiscott	NULL
.	NULL

1998	NULL
.	NULL

Inducible	NULL
expression	NULL
of	NULL
IxBa	NULL
repressor	NULL
mutants	NULL
interferes	NULL
with	NULL
NF-	NULL
«	NULL
B	NULL
activity	NULL
and	NULL
HIV-1	NULL
replication	NULL
in	NULL
Jurkat	NULL
T	NULL
cells	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:7431-7440	NULL
.	NULL

Lai	NULL
,	NULL
J.-H.	NULL
,	NULL
G.	NULL
Horvath	NULL
,	NULL
J.	NULL
Subleski	NULL
,	NULL
J.	NULL
Bruder	NULL
,	NULL
P.	NULL
Ghosh	NULL
,	NULL
and	NULL
T.-H.	NULL
Tan	NULL
.	NULL

1995	NULL
.	NULL

RelA	NULL
is	NULL
a	NULL
potent	NULL
transcriptional	NULL
activator	NULL
of	NULL
the	NULL
CD28	NULL
response	NULL
element	NULL
within	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:4260-4271	NULL
.	NULL

Leithiuser	NULL
,	NULL
F.	NULL
,	NULL
J.	NULL
Dhein	NULL
,	NULL
G.	NULL
Mechtersheimer	NULL
,	NULL
K.	NULL
Koretz	NULL
,	NULL
S.	NULL
Briiderlein	NULL
,	NULL
C.	NULL
Henne	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
K.-M.	NULL
Debatin	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
and	NULL
P.	NULL
Moller	NULL
.	NULL

1993	NULL
.	NULL

Constitutive	NULL
and	NULL
induced	NULL
expression	NULL
of	NULL
APO-1	NULL
,	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
nerve	NULL
growth	NULL
factor/tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
superfamily	NULL
,	NULL
in	NULL
normal	NULL
and	NULL
neoplastic	NULL
cells	NULL
.	NULL

Lab	NULL
.	NULL

Investig	NULL
.	NULL

69:415-429	NULL
.	NULL

Leverkus	NULL
,	NULL
M.	NULL
,	NULL
M.	NULL
Yaar	NULL
,	NULL
and	NULL
B	NULL
.	NULL

A.	NULL
Gilchrest	NULL
.	NULL

1997	NULL
.	NULL

Fas/Fas	NULL
ligand	NULL
interaction	NULL
contributes	NULL
to	NULL
UV-induced	NULL
apoptosis	NULL
in	NULL
human	NULL
keratinocytes	NULL
.	NULL

Exp	NULL
.	NULL

Cell	NULL
Res	NULL
.	NULL

232:255-262	NULL
.	NULL

Locker	NULL
,	NULL
J	NULL
.	NULL

1996	NULL
.	NULL

Transcription	NULL
factors-essential	NULL
data	NULL
.	NULL

John	NULL
Wiley	NULL
&	NULL
Sons	NULL
,	NULL
Chichester	NULL
,	NULL
West	NULL
Sussex	NULL
,	NULL
United	NULL
Kingdom	NULL
.	NULL

Marienfeld	NULL
,	NULL
R.	NULL
,	NULL
M.	NULL
Neumann	NULL
,	NULL
S.	NULL
Chuypilo	NULL
,	NULL
C.	NULL
Escher	NULL
,	NULL
B.	NULL
Kneitz	NULL
,	NULL
A.	NULL
Avots	NULL
,	NULL
A.	NULL
Schimpl	NULL
,	NULL
and	NULL
E.	NULL
Serfling	NULL
.	NULL

1997	NULL
.	NULL

Cyclosporin	NULL
A	NULL
interferes	NULL
with	NULL
the	NULL
inducible	NULL
degradation	NULL
of	NULL
NF-	NULL
«	NULL
B	NULL
inhibitors	NULL
,	NULL
but	NULL
not	NULL
with	NULL
the	NULL
processing	NULL
of	NULL
p105/NFkB1	NULL
in	NULL
T	NULL
cells	NULL
.	NULL

Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

27:1601-1609	NULL
.	NULL

Miyawaki	NULL
,	NULL
T.	NULL
,	NULL
T.	NULL
Uehara	NULL
,	NULL
R.	NULL
Nibu	NULL
,	NULL
T.	NULL
Tsuji	NULL
,	NULL
A.	NULL
Yachie	NULL
,	NULL
S.	NULL
Yonehara	NULL
,	NULL
and	NULL
N.	NULL
Taniguchi	NULL
.	NULL

1992	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
apoptosis-related	NULL
Fas	NULL
antigen	NULL
on	NULL
lymphocyte	NULL
subpopulations	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149	NULL
;	NULL
3753-3758	NULL
.	NULL

Muller	NULL
,	NULL
C.	NULL
W.	NULL
,	NULL
F.	NULL
A.	NULL
Rey	NULL
,	NULL
M.	NULL
Sodeoka	NULL
,	NULL
G.	NULL
L.	NULL
Verdine	NULL
,	NULL
and	NULL
S.	NULL
C.	NULL
Harrison	NULL
.	NULL

1995	NULL
.	NULL

Structure	NULL
of	NULL
the	NULL
NF-kB	NULL
p50	NULL
homodimer	NULL
bound	NULL
to	NULL
DNA	NULL
.	NULL

Nature	NULL
373	NULL
:	NULL
311-317	NULL
.	NULL

Muller	NULL
,	NULL
M.	NULL
,	NULL
S.	NULL
Strand	NULL
,	NULL
H.	NULL
Hug	NULL
,	NULL
E.-M.	NULL
Heinemann	NULL
,	NULL
H.	NULL
Walczak	NULL
,	NULL
W.	NULL
J.	NULL
Hoff-mann	NULL
,	NULL
W.	NULL
Stremmel	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
and	NULL
P.	NULL
R.	NULL
Galle	NULL
.	NULL

1997	NULL
.	NULL

Drug-induced	NULL
apoptosis	NULL
in	NULL
hepatoma	NULL
cells	NULL
is	NULL
mediated	NULL
by	NULL
the	NULL
CD95	NULL
(	NULL
APO-1/Fas	NULL
)	NULL
receptor/	NULL
ligand	NULL
system	NULL
and	NULL
involves	NULL
activation	NULL
of	NULL
wild-type	NULL
p53	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Investig	NULL
.	NULL

99:403-413	NULL
.	NULL

Muzio	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
M.	NULL
Chinnaiyan	NULL
,	NULL
F.	NULL
C.	NULL
Kischkel	NULL
,	NULL
K.	NULL
O'Rourke	NULL
,	NULL
A.	NULL
Shevchenko	NULL
,	NULL
J.	NULL
Ni	NULL
,	NULL
C.	NULL
Scaffidi	NULL
,	NULL
J.	NULL
D.	NULL
Bretz	NULL
,	NULL
M.	NULL
Zhang	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
M.	NULL
Mann	NULL
,	NULL
P.	NULL
H.	NULL
Krammer	NULL
,	NULL
M.	NULL
E.	NULL
Peter	NULL
,	NULL
and	NULL
V.	NULL
M.	NULL
Dixit	NULL
.	NULL

1996	NULL
.	NULL

FLICE	NULL
,	NULL
a	NULL
novel	NULL
FADD-homologous	NULL
ICE/Ced-3-like	NULL
protease	NULL
,	NULL
is	NULL
recruited	NULL
to	NULL
the	NULL
CD95	NULL
(	NULL
Fas/APO-1	NULL
)	NULL
death	NULL
inducing	NULL
signaling	NULL
complex	NULL
.	NULL

Cell	NULL
85:817-827	NULL
.	NULL

Nagata	NULL
,	NULL
S.	NULL
1997	NULL
.	NULL

Apoptosis	NULL
by	NULL
death	NULL
factor	NULL
.	NULL

Cell	NULL
88:355-365	NULL
.	NULL

Sp1	NULL
is	NULL
a	NULL
component	NULL
of	NULL
the	NULL
cytokine-inducible	NULL
enhancer	NULL
in	NULL
the	NULL
promoter	NULL
of	NULL
vascular	NULL
cell	NULL
adhesion	NULL
molecule-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:28903-28909	NULL
.	NULL

Owen-Schaub	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
R.	NULL
Radinsky	NULL
,	NULL
E.	NULL
Kruzel	NULL
,	NULL
K.	NULL
Berry	NULL
,	NULL
and	NULL
S.	NULL
Yonehara	NULL
.	NULL

1994	NULL
.	NULL

Anti-Fas	NULL
on	NULL
nonhematopoictic	NULL
tumors	NULL
:	NULL
levels	NULL
of	NULL
Fas/APO-1	NULL
and	NULL
bcl-2	NULL
are	NULL
not	NULL
predictive	NULL
of	NULL
biological	NULL
responsiveness	NULL
.	NULL

Cancer	NULL
Res	NULL
.	NULL

54:1580-1586	NULL
.	NULL

Owen-Schaub	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
S.	NULL
Yonehara	NULL
,	NULL
W.	NULL
L.	NULL
Crump	NULL
,	NULL
and	NULL
E.	NULL
A.	NULL
Grimm	NULL
.	NULL

1992	NULL
.	NULL

DNA	NULL
fragmentation	NULL
and	NULL
cell	NULL
death	NULL
is	NULL
selectively	NULL
triggered	NULL
in	NULL
activated	NULL
human	NULL
lymphocytes	NULL
by	NULL
Fas	NULL
antigen	NULL
engagement	NULL
.	NULL

Cell	NULL
.	NULL

Immunol	NULL
.	NULL

140:197-205	NULL
.	NULL

Owen-Schaub	NULL
,	NULL
L.	NULL
B.	NULL
,	NULL
W.	NULL
Zhang	NULL
,	NULL
J.	NULL
C.	NULL
Cusack	NULL
,	NULL
L.	NULL
S.	NULL
Angelo	NULL
,	NULL
S.	NULL
M.	NULL
Santee	NULL
,	NULL
T.	NULL
Fujiwara	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Roth	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Deisseroth	NULL
,	NULL
W.-W.	NULL
Zhang	NULL
,	NULL
E.	NULL
Kruzel	NULL
,	NULL
and	NULL
R.	NULL
Radinsky	NULL
.	NULL

1995	NULL
.	NULL

Wild-type	NULL
human	NULL
p53	NULL
and	NULL
a	NULL
temperature-sensitive	NULL
mutant	NULL
induce	NULL
Fas/APO-1	NULL
expression	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15:3032-3040	NULL
.	NULL

Pahl	NULL
,	NULL
H.	NULL
L.	NULL
,	NULL
B.	NULL
Kraub	NULL
,	NULL
K.	NULL
Schulze-Osthoff	NULL
,	NULL
T.	NULL
Decker	NULL
,	NULL
E.	NULL
B.-M.	NULL
Traenckner	NULL
,	NULL
M.	NULL
Vogt	NULL
,	NULL
C.	NULL
Myers	NULL
,	NULL
T.	NULL
Parks	NULL
,	NULL
P.	NULL
Warring	NULL
,	NULL
A.	NULL
Mihlbacher	NULL
,	NULL
A.	NULL
P.	NULL
Czernilofsky	NULL
,	NULL
and	NULL
P.	NULL
A.	NULL
Baeuerle	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
immunosuppressive	NULL
fungal	NULL
metabolite	NULL
gliotoxin	NULL
specifically	NULL
inhibits	NULL
transcription	NULL
factor	NULL
NF-	NULL
«	NULL
B	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

183:1829-1840	NULL
.	NULL

Park	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
S.	NULL
Y.	NULL
Lee	NULL
,	NULL
G.	NULL
Kandala	NULL
,	NULL
S.	NULL
Y.	NULL
Lee	NULL
,	NULL
and	NULL
Y.	NULL
Choi	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
novel	NULL
gene	NULL
product	NULL
that	NULL
couples	NULL
TCR	NULL
signaling	NULL
to	NULL
Fas	NULL
(	NULL
CD95	NULL
)	NULL
expression	NULL
in	NULL
activation-induced	NULL
cell	NULL
death	NULL
.	NULL

Immunity	NULL
4:583-591	NULL
.	NULL

Parry	NULL
,	NULL
G.	NULL
C.	NULL
,	NULL
and	NULL
N.	NULL
Mackman	NULL
.	NULL

1994	NULL
.	NULL

A	NULL
set	NULL
of	NULL
inducible	NULL
genes	NULL
expressed	NULL
by	NULL
activated	NULL
human	NULL
monocytic	NULL
and	NULL
endothelial	NULL
cells	NULL
contain	NULL
xB-like	NULL
sites	NULL
that	NULL
specifically	NULL
bind	NULL
c-Rel-p65	NULL
heterodimers	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269:20823-20825	NULL
.	NULL

Pavletich	NULL
,	NULL
N.	NULL
P.	NULL
,	NULL
and	NULL
C.	NULL
O.	NULL
Pabo	NULL
.	NULL

1991	NULL
.	NULL

Zinc	NULL
finger-DNA	NULL
recognition	NULL
:	NULL
crystal	NULL
structure	NULL
of	NULL
a	NULL
Zif268-DNA	NULL
complex	NULL
at	NULL
2.1	NULL
A	NULL
.	NULL

Science	NULL
252:809-817	NULL
.	NULL

Perkins	NULL
,	NULL
N.	NULL
D.	NULL
,	NULL
N.	NULL
L.	NULL
Edwards	NULL
,	NULL
C.	NULL
S.	NULL
Duckett	NULL
,	NULL
A	NULL
.	NULL

B.	NULL
Agranoff	NULL
,	NULL
R.	NULL
M.	NULL
Schmid	NULL
,	NULL
and	NULL
G.	NULL
J.	NULL
Nabel	NULL
.	NULL

1993	NULL
.	NULL

A	NULL
cooperative	NULL
interaction	NULL
between	NULL
NF-	NULL
«	NULL
B	NULL
and	NULL
Sp1	NULL
is	NULL
2108	NULL
51	NULL
.	NULL

52	NULL
.	NULL

53	NULL
.	NULL

54	NULL
.	NULL

55	NULL
.	NULL

56	NULL
.	NULL

57	NULL
.	NULL

58	NULL
.	NULL

CHAN	NULL
ET	NULL
AL	NULL
.	NULL

required	NULL
for	NULL
HIV-1	NULL
enhancer	NULL
activation	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3551-3558	NULL
.	NULL

Rothe	NULL
,	NULL
J.	NULL
,	NULL
H.	NULL
Bluethmann	NULL
,	NULL
R.	NULL
Gentz	NULL
,	NULL
W.	NULL
Lesslauer	NULL
,	NULL
and	NULL
M.	NULL
Steinmetz	NULL
.	NULL

1993	NULL
.	NULL

Genomic	NULL
organization	NULL
and	NULL
promoter	NULL
function	NULL
of	NULL
the	NULL
murine	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
B	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Immunol	NULL
.	NULL

30:165-175	NULL
.	NULL

Santee	NULL
,	NULL
S.	NULL
M.	NULL
,	NULL
and	NULL
L.	NULL
B.	NULL
Owen-Schaub	NULL
.	NULL

1996	NULL
.	NULL

Human	NULL
tumor	NULL
necrosis	NULL
factor	NULL
receptor	NULL
p75/80	NULL
(	NULL
CD120b	NULL
)	NULL
gene	NULL
structure	NULL
and	NULL
promoter	NULL
characterization	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271:21151-21159	NULL
.	NULL

Sato	NULL
,	NULL
T.	NULL
,	NULL
S.	NULL
Irie	NULL
,	NULL
S.	NULL
Kitada	NULL
,	NULL
and	NULL
J.	NULL
C.	NULL
Reed	NULL
.	NULL

1995	NULL
.	NULL

FAP-1	NULL
:	NULL
A	NULL
protein	NULL
tyrosine	NULL
phosphatase	NULL
that	NULL
associates	NULL
with	NULL
Fas	NULL
.	NULL

Science	NULL
268:411-415	NULL
.	NULL

Sehgal	NULL
,	NULL
A.	NULL
,	NULL
N.	NULL
Patil	NULL
,	NULL
and	NULL
M.	NULL
Chao	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
constitutive	NULL
promoter	NULL
directs	NULL
expression	NULL
of	NULL
the	NULL
nerve	NULL
growth	NULL
factor	NULL
receptor	NULL
gene	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:3160-3167	NULL
.	NULL

Shaw	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
R.	NULL
Kamen	NULL
.	NULL

1986	NULL
.	NULL

A	NULL
conserved	NULL
AU	NULL
sequence	NULL
from	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
GM-CSF	NULL
mRNA	NULL
mediates	NULL
selective	NULL
mRNA	NULL
degra-dation	NULL
.	NULL

Cell	NULL
46:659-667	NULL
.	NULL

Sherka	NULL
,	NULL
C.	NULL
,	NULL
E.	NULL
L.	NULL
Decker	NULL
,	NULL
and	NULL
P.	NULL
F.	NULL
Zipfel	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
regulatory	NULL
element	NULL
in	NULL
the	NULL
human	NULL
interleukin	NULL
2	NULL
gene	NULL
promoter	NULL
is	NULL
a	NULL
binding	NULL
site	NULL
for	NULL
the	NULL
zinc	NULL
finger	NULL
proteins	NULL
Sp1	NULL
and	NULL
EGR-1	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270:22500-22506	NULL
.	NULL

Sjottem	NULL
,	NULL
E.	NULL
,	NULL
C.	NULL
Andersen	NULL
,	NULL
and	NULL
T.	NULL
Johansen	NULL
.	NULL

1997	NULL
.	NULL

Structural	NULL
and	NULL
functional	NULL
analyses	NULL
of	NULL
DNA	NULL
bending	NULL
induced	NULL
by	NULL
Sp1	NULL
family	NULL
transcription	NULL
factors	NULL
.	NULL

J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

267:490-504	NULL
.	NULL

Stein	NULL
,	NULL
B.	NULL
,	NULL
A.	NULL
S.	NULL
Baldwin	NULL
,	NULL
Jr.	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
W.	NULL
C.	NULL
Greene	NULL
,	NULL
P.	NULL
Angel	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1993	NULL
.	NULL

Cross-coupling	NULL
of	NULL
the	NULL
NF-	NULL
«	NULL
B	NULL
p65	NULL
and	NULL
Fos/Jun	NULL
transcription	NULL
59	NULL
.	NULL

60	NULL
.	NULL

61	NULL
.	NULL

62	NULL
.	NULL

63	NULL
.	NULL

64	NULL
.	NULL

65	NULL
.	NULL

Mor	NULL
.	NULL

CELL	NULL
.	NULL

BioL	NULL
.	NULL

factors	NULL
produces	NULL
potentiated	NULL
biological	NULL
function	NULL
.	NULL

EMBO	NULL
J	NULL
.	NULL

12:3879-3891	NULL
.	NULL

Suzuki	NULL
,	NULL
L	NULL
,	NULL
and	NULL
P.	NULL
J.	NULL
Fink	NULL
.	NULL

1998	NULL
.	NULL

Maximal	NULL
proliferation	NULL
of	NULL
cytotoxic	NULL
T	NULL
lymphocytes	NULL
requires	NULL
reverse	NULL
signaling	NULL
through	NULL
Fas	NULL
ligand	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

187	NULL
;	NULL
123-128	NULL
.	NULL

Takabashi	NULL
,	NULL
T.	NULL
,	NULL
M.	NULL
Tanaka	NULL
,	NULL
C.	NULL
I.	NULL
Brannan	NULL
,	NULL
N.	NULL
A.	NULL
Jenkins	NULL
,	NULL
N.	NULL
G.	NULL
Copeland	NULL
,	NULL
T.	NULL
Suda	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1994	NULL
.	NULL

Generalized	NULL
lymphoproliferative	NULL
disease	NULL
in	NULL
mice	NULL
,	NULL
caused	NULL
by	NULL
a	NULL
point	NULL
mutation	NULL
in	NULL
the	NULL
Fas	NULL
ligand	NULL
.	NULL

Cell	NULL
76:969-976	NULL
.	NULL

Tanaka	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Ito	NULL
,	NULL
S.	NULL
Adachi	NULL
,	NULL
H.	NULL
Akimoto	NULL
,	NULL
T.	NULL
Nishikawa	NULL
,	NULL
T.	NULL
Kasajima	NULL
,	NULL
F.	NULL
Marumo	NULL
,	NULL
and	NULL
M.	NULL
Hiroe	NULL
.	NULL

1994	NULL
.	NULL

Hypoxia	NULL
induces	NULL
apoptosis	NULL
with	NULL
enhanced	NULL
expression	NULL
of	NULL
Fas	NULL
antigen	NULL
messenger	NULL
RNA	NULL
in	NULL
cultured	NULL
neonatal	NULL
rat	NULL
cardio-myocytes	NULL
.	NULL

Circ	NULL
.	NULL

Res	NULL
.	NULL

75:426-433	NULL
.	NULL

Thanos	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
T.	NULL
Maniatis	NULL
.	NULL

1992	NULL
.	NULL

The	NULL
high	NULL
mobility	NULL
group	NULL
protein	NULL
HMG	NULL
I	NULL
(	NULL
Y	NULL
)	NULL
is	NULL
required	NULL
for	NULL
NF-	NULL
«	NULL
B-dependent	NULL
virus	NULL
induction	NULL
of	NULL
the	NULL
human	NULL
IFN-B	NULL
gene	NULL
.	NULL

Cell	NULL
71:777-789.	NULL
van	NULL
Parijs	NULL
,	NULL
L.	NULL
,	NULL
A.	NULL
Ibraghimoy	NULL
,	NULL
and	NULL
A.	NULL
K.	NULL
Abbas	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
roles	NULL
of	NULL
costimulation	NULL
and	NULL
Fas	NULL
in	NULL
T-cell	NULL
apoptosis	NULL
and	NULL
peripheral	NULL
tolerance	NULL
.	NULL

Immunity	NULL
4:321-326	NULL
.	NULL

Verma	NULL
,	NULL
I.	NULL
M.	NULL
,	NULL
J.	NULL
K.	NULL
Stevenson	NULL
,	NULL
E.	NULL
M.	NULL
Schwartz	NULL
,	NULL
D.	NULL
Van	NULL
Antwerp	NULL
,	NULL
and	NULL
S.	NULL
Miyamoto	NULL
.	NULL

1995	NULL
.	NULL

Rel/NF-	NULL
«	NULL
B/IxB	NULL
family	NULL
:	NULL
intimate	NULL
tales	NULL
of	NULL
association	NULL
and	NULL
dissociation	NULL
.	NULL

Genes	NULL
Dev	NULL
.	NULL

9:2723-2735	NULL
.	NULL

Watanabe-Fukunaga	NULL
,	NULL
R.	NULL
,	NULL
C.	NULL
I.	NULL
Brannan	NULL
,	NULL
N.	NULL
G.	NULL
Copeland	NULL
,	NULL
N.	NULL
A.	NULL
Jenkins	NULL
,	NULL
and	NULL
S.	NULL
Nagata	NULL
.	NULL

1992	NULL
.	NULL

Lymphoproliferation	NULL
disorder	NULL
in	NULL
mice	NULL
explained	NULL
by	NULL
defects	NULL
in	NULL
Fas	NULL
antigen	NULL
that	NULL
mediates	NULL
apoptosis	NULL
.	NULL

Nature	NULL
356:314-317	NULL
.	NULL

